

24	Abbreviations
25	1 Abstract
26	2 Introduction
27	3 Methods
28	3.1 Study Plan
29	3.1.1 Purpose
30	3.1.2 Organization
31	3.1.2.1 <i>Trial coordinator</i>
32	3.1.2.2 <i>Chemical management group</i>
33	3.1.2.3 <i>Data analysis group</i>
34	3.1.2.4 <i>Record management group</i>
35	3.1.2.5 <i>Lead laboratory</i>
36	3.1.2.6 <i>Participating laboratories</i>
37	3.1.3 Study design
38	3.1.3.1 <i>Training of personnel at the participating laboratories</i>
39	3.1.3.2 <i>Phase 0</i>
40	3.1.3.2 <i>Phase I</i>
41	3.1.3.3 <i>Phase II</i>
42	3.1.3.4 <i>Phase III</i>
43	3.1.4 Success criteria
44	3.2 Summary of protocol
45	3.2.1 Culturing HCE-T cells
46	3.2.2 Preparation of collagen vitrigel membrane chambers
47	3.2.3 Reconstruction of a human corneal epithelium model
48	3.2.4 Mode of action in vivo
49	3.2.5 Calculation of TEER values for HCE models
50	3.2.6 Exposure to test chemicals
51	3.2.7 Calculating eye irritancy of test chemicals
52	3.2.8 Correlation with the UN GHS classification
53	3.2.9 Commercial availability and/or intellectual property rights to the test method and its
54	components
55	
56	3.3 Test chemicals
57	3.3.1 Selection and distribution of test chemicals
58	3.3.2 Test chemicals for Phases 0, I, II, and III
59	3.3.2.1 <i>Test chemicals for Phase 0</i>
60	3.3.2.2 <i>Test chemicals for Phase I</i>

61	3.3.2.3	<i>Test chemicals for Phase II</i>
62	3.3.2.4	<i>Test chemicals for Phase III</i>
63	3.4	Quality assurance
64	3.5	Record collection and analysis
65	4	Results
66	4.1	Study duration
67	4.1.1	Phase 0
68	4.1.2	Phase I
69	4.1.3	Phase II
70	4.1.4	Phase III
71	4.2	Quality assurance
72	5	Discussion
73	5.1	Purpose of the Validation
74	5.2	Transferability
75	5.3	Within- and between-laboratory reproducibility
76	5.4	Predictive capacity and relevance
77	5.5	Applicability domain
78	5.6	Other analysis
79	5.7	Comparison with other alternative to ocular irritation assay
80	6	Conclusion
81	7	References
82		
83	8	Appendix
84	8.1	Study Plan ver.4
85	8.2	Protocol ver.1.80e
86	8.3	Data sheet format
87	8.4	Selection of test chemicals
88	8.5	Statistical analysis report for Vitrigel-EIT validation study
89	8.6	Report on the Quality assurance for Vitrigel-EIT validation study
90	8.7	Minutes of VMT meetings
91	8.8	Result of the Vitrigel-EIT at the lead laboratory for 57 chemicals
92	8.9	The draft list of proficiency chemicals
93	8.10	Yamaguchi H, et al., 2016. J. Applied Toxicology accepted
94	8.11	The raw data for the 118 in-house chemicals
95	8.12	Background by biostatistician
96	8.13	Predictive capacity of the Vitrigel-EIT for 114 chemicals considering DRD
97	8.14	Result of the Vitrigel-EIT at the lead laboratory for 114 chemicals
98		

100 **Abbreviations**

CVM	Collagen Vitrigel Membrane
EIT	Eye Irritancy Test
EURL ECVAM	European Union Reference Laboratory for Alternatives to Animal Testing
ECETOC	European Centre for Ecotoxicology and Toxicology of Chemicals
GHS	Globally Harmonized Systems of Classification and Labeling
GLP	Good Laboratory Practice
HCE	Human Corneal Epithelium
ICCVAM	Interagency Coordinating Committee on the Validation of Alternative Methods
JaCVAM	Japanese Centre for the Validation of Alternative Methods
NI	Non-irritant
NICEATM	National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods
OECD	Organization for Economic Co-operation and Development
PET	Polyethylene terephthalate
SOP	Standard operating procedure
STE	Short time exposure
TEER	Transepithelial electrical resistance
UN	United Nations
VMT	Validation management team

102 **1 Abstract**

103 Collagen vitrigel membrane (CVM) comprises high-density collagen fibrils that are equivalent to in
104 vivo connective tissues and is easily handled with tweezers. Takezawa et al. developed a human
105 corneal epithelium (HCE) model by three-dimensional culturing of HCE-T cells on a CVM scaffold
106 in a chamber that provided an air–liquid interface culture system. They further used their HCE model
107 to establish a new test method, known as the Vitrigel-eye irritancy test (Vitrigel-EIT) method, which
108 can be used to estimate the ocular irritation potential of test chemicals by analyzing relative changes
109 in transepithelial electrical resistance (TEER) over time.

110 This trial was conducted to validate the reliability and relevance of the Vitrigel-EIT method at three
111 participating laboratories in the spirit of GLP by verifying the within- and between-laboratory
112 reproducibility for 42 test chemicals as well as the capacity for distinguishing non-irritants from
113 irritants in a bottom-up approach.

114 The results showed 80–100% within-laboratory reproducibility at all three laboratories and an
115 excellent between-laboratory reproducibility of 92%. Unfortunately, the predictive capacity for
116 distinguishing non-irritants from irritants per UN GHS categories in a bottom-up approach was not
117 favorable because of false negative rates as high as 17%. After considerable review of the data,
118 however, it was determined that excluding test chemicals with a pH level of 5 or less as well as solid
119 test chemicals with a logP value of 2.5 or more and a density of less than 0.95 g/cm³ or greater than
120 1.10 g/cm³ improved the false negative rate to as low as 7%.

121 These results suggest that, with a carefully defined applicability domain, the Vitrigel-EIT method is a
122 useful alternative to the Draize test for distinguishing test chemicals that are ocular non-irritants from
123 those that are irritants.

124 **2 Introduction**

125 Collagen vitrigel membrane (CVM) comprises high-density collagen fibrils that are equivalent to
126 vivo connective tissues and is easily handled with tweezers. In addition, it has excellent transparency
127 and permeability of high molecular weight proteins and is now used as a cell culture scaffold in a
128 number of advanced studies (Takezawa et al., 2004, 2007a–c). Takezawa et al. developed a corneal
129 epithelium model utilizing a CVM scaffold that facilitates the maintenance of corneal epithelial
130 phenotype in a monolayer of rabbit corneal epithelial cells (Takezawa et al., 2008). Still, there are
131 significant differences in sensitivity to exogenous chemicals between humans and rabbits, so they also
132 developed a human corneal epithelium (HCE) model by three-dimensional culturing of HCE-T cells
133 on the CVM scaffold in a chamber that provided an air–liquid interface culture system (Takezawa et
134 al., 2011a). Here, HCE-T cells are a SV40-immortalized cell strain established by Araki-Sasaki et al
135 (Araki-Sasaki et al., 1995). The HCE-T cell line is one of the most favored human cornea epithelium-
136 derived cells and frequently used for various cornea epithelium-related studies because it is easy to
137 maintain the stable characteristics of cornea epithelial cells in culture (Kim et al., 2016, Yamasaki et
138 al., 2009). The scaffold was fabricated on a polyethylene terephthalate (PET) membrane of a Millicell
139 chamber suitable for assaying the transepithelial electrical resistance (TEER) of epithelial cells. The
140 TEER assay is considered a suitable method for in vivo evaluation of the integrity of the tight junction
141 of the corneal epithelium (Uematsu et al., 2007). Takezawa et al. then used the HCE model to verify
142 that relative change over time in TEER is a useful indicator for assessing the ocular irritancy of four
143 test chemicals, including mild irritants (Takezawa et al., 2011a). The HCE model, however, is not
144 considered suitable for immuno-histological analyses due to difficulties in preparing frozen sections
145 with a PET membrane. To overcome this inconvenience, they developed a novel chamber that merely
146 accompanies a CVM without the PET membrane as well as established a process for its mass
147 production (Takezawa et al., 2011b, 2012). More recently, they established a new test method for
148 estimating the ocular irritancy of test chemicals by analyzing the relative changes over time in TEER
149 after exposing HCE models reconstructed in CVM chambers to test chemicals. This new test method
150 is called the Vitrigel eye irritancy test (Vitrigel-EIT) method. Thus far, thirty chemicals have been

151 classified successfully as irritants or non-irritants without false negatives using the Vitrigel-EIT
152 method (Yamaguchi et al., 2013).

153 In association with the International Collaboration on Alternative Test Methods (ICATM), an
154 international validation management team (VMT) was organized to validate the reliability and
155 relevance of this test method, and a validation study was performed with the cooperation of three
156 Japanese laboratories. Testing was conducted using a protocol developed by Yamaguchi and
157 Takezawa using test chemicals distributed via the Japanese Center for the Validation of Alternative
158 methods (JaCVAM). Descriptive statistics are used to summarize the data obtained from the testing.
159 The aim of this trial is to validate the capability of the Vitrigel-EIT method as well as to assess
160 transferability and between-laboratory reproducibility in preparation for incorporating this test into
161 the screening of test chemicals for the eye irritation potential in accordance with the United Nations'
162 Globally Harmonized System of Classification and Labelling of Chemicals (GHS) categories (United
163 Nations, 2013). This multi-phase validation study of the Vitrigel-EIT method was undertaken in
164 accordance with:

- 165 i) the principles and criteria documented in the Organization for Economic Co-operation and
166 Development (OECD) No. 34 Guidance Document on the Validation and International
167 Acceptance of New or Updated Test Methods for Hazard Assessment (OECD, 2005),
- 168 ii) the Modular Approach to Validation (Hartung et al., 2004), and
- 169 iii) the concepts discussed in The Principles of Good Laboratory Practice: Application to In Vitro
170 Toxicological Studies (Cooper-Hannan et al., 1999).

171 Testing performed as part of a validation study should ideally be performed in accordance with GLP
172 (OECD, 1998) and necessarily include, without being limited to, the use of standard operating
173 procedures (SOP) and adequate recording of data as well as suitable reporting of results and archival
174 record keeping.

175 The “modular approach to validation” is a general conceptual framework for documenting the
176 validation of a test method (Hartung et al., 2004; OECD, 2005). In this approach, the information
177 needed to support the validity of the method is organized into modules, as follows.

- 178 • Module 1: Test Definition
- 179 • Module 2: Within-laboratory repeatability and reproducibility
- 180 • Module 3: Between-laboratory transferability
- 181 • Module 4: Between-laboratory reproducibility
- 182 • Module 5: Predictive capacity
- 183 • Module 6: Applicability domain
- 184 • Module 7: Performance standards

185 The modular approach introduced by Hartung et al. (2004) allows the use of datasets from a variety
186 of sources, and this principle was applied in our assessment of the scientific validity of the Vitrigel-
187 EIT method. As a specific goal, this validation study was designed to clarify whether or not the
188 Vitrigel-EIT test method is a useful alternative to the Draize test method in a bottom-up approach for
189 distinguishing chemical substance.

190

191 **3 Methods**

192 **3.1 Study Plan**

193 3.1.1 Purpose

194 This validation study is designed to assess the reliability (within- and between-laboratory
195 reproducibility) and relevance (predictive capacity) of the Vitrigel-EIT method using a challenging
196 set of test chemicals for which high quality in vitro and in vivo data are available. The test chemicals
197 are to include each type of UN GHS category as classified by in vivo data and predictive capacity is
198 to be assessed primarily in accordance with UN GHS classification in a bottom-up approach (Scott,
199 2010).

200

201 3.1.2 Organization

202 Members of the VMT contribute their collective expertise in the underlying science and scientific
203 design, management, and evaluation of validation studies. The management structure for this
204 validation study of the Vitrigel-EIT method is shown in Fig. 1.

205 The VMT is responsible for overseeing the conduct of the validation study, including signing and
 206 dating the approval of all protocols, study plans, reports, and amendments.


207 The members of the VMT as well as their respective roles and expertise for this validation study of
 208 the Vitrigel-EIT method are shown in Table 1 and Fig. 1.

209

210 Table 1. The Vitrigel-EIT Validation Management Team

Name	Role and expertise	Affiliation
Hajime Kojima	Trial coordinator, Chemical management and Quality assurance	Japanese Center for the Validation of Alternative Methods (JaCVAM), National Institute of Health Sciences (NIHS)
Toshiaki Takezawa Hiroyuki Yamaguchi	Developer of this assay and expertise underlying science as the lead laboratory	Institute of Agrobiological Sciences (NIAS), National Agriculture and Food Research Organization (NARO)
Takashi Sozu	Data analysis and biostatistics dossier	Tokyo Univ. of Science
Liaison members		
Nicole Kleinstreuer	Validation study expertise	National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)/ Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), USA
Michael-Wilhelm SCHAEFFER	Validation study expertise	European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Italy
Lim, Chae-Hyung	Validation study expertise	Korean Center for the Validation of Alternative Methods (KoCVAM), Korea

Wannhsin Chen	Validation study expertise	Industrial Technology Research Institute, (ITRI), Taiwan
---------------	----------------------------	---



^aSeveral Quality Assurance units might be involved in a multi-study trial.
Dashed lines indicate assurance staff involvement.

211

212

Fig.1. Management Structure for the Vitrigel-EIT validation study

213

214 3.1.2.1 Trial coordinator

215 A trial coordinator was appointed by the VMT to be responsible for preparing draft study plans, a
216 study protocol, and a list of test chemicals as well as to convene ad hoc VMT meetings for review and
217 finalization of the study plan, the study protocol, and the test chemical list. The trial coordinator was
218 also responsible for other administrative duties related to the validation study.

219

220 3.1.2.2 Chemical management group

221 The chemical management group comprised at least one member selected from the VMT and was
222 responsible for preparing a list of test chemicals as well as conferring with the trial coordinator to
223 finalize the list test chemicals to be used in the validation study. It also prepared and distributed non-
224 coded or coded lists of test chemicals to chemical distributors.

225

226 3.1.2.3 Data analysis group

227 The data analysis group comprised at least one member selected from the VMT and was responsible
228 for providing an objective analysis of data obtained in this validation study as well as for performing

229 statistical processing of the data.

230 *3.1.2.4 Record management group*

231 The record management group comprised at least one member selected from the VMT as well as a
232 representative of the lead laboratory was responsible for preparing the test protocol, the test chemical
233 preparation sheets, blank data sheets, and any other necessary materials as well as for distributing
234 these materials to the participating laboratories. It also collected the completed forms and data sheets
235 after testing, reviewed the records for errors and omissions, and requested correction as necessary.

236

237 *3.1.2.5 Lead laboratory*

238 The lead laboratory represents the test developers and was responsible for providing the test method
239 protocol as well as test chemical preparation record forms, blank data sheets, and all other necessary
240 documentation. The lead laboratory was also responsible for providing revised versions of the
241 protocol as necessary throughout the entire validation study. The VMT consulted with both the lead
242 laboratory and the other participating laboratories on technical issues.

243

244 *3.1.2.6 Participating laboratories*

245 The following three laboratories in Japan participated in the testing of substances using the Vitrigel-
246 EIT method. The name of the on-site study director is given in parenthesis.

247 **Lab A:** Hatano Research Institute, Food and Drug Safety Center (FDSC), Hatano, Kanagawa
248 (Mika Watanabe)

249 **Lab B:** Bozo Research Center (BRC), Tokyo (Takayuki Fukuda)

250 **Lab C:** Daicel Corporation (Daicel), Himeji, Hyogo (Kunihiko Yamashita)

251 All three of these laboratories were naïve and were selected for participation by the VMT after
252 practical training that provided a good indication of the robustness of the test method.

253 A coordinator from each of these three laboratories participated in VMT activities as observers and
254 was responsible for ensuring that the tests were performed in accordance with the study protocol as
255 well as for filling out and submitting all necessary records and forms upon completion of testing.

256 3.1.3 Study design

257 This validation study of the Vitrigel-EIT method was carried out in four phases in accordance with
258 the study plan as described in Appendix 8.1 and summarized in Table 2.

259

260 Table 2. Overview of the Vitrigel-EIT validation study

Phase	The number of the test chemicals	The number of the repetitions	Examination
0	5	3	Within- laboratory transferability
I	10	3	Between- laboratory transferability & Within- and between- laboratory reproducibility
II	10	1	Between- laboratory reproducibility
III	36	1	Between- laboratory reproducibility and predictability

261

262 3.1.3.1 Training of personnel at the participating laboratories

263 A technical transfer workshop to explain the principles of and protocol for validation of the Vitrigel-
264 EIT method was held May 22 and 23, 2013, with personnel from all three laboratories in attendance.
265 Instructors from the lead laboratory explained the test method while demonstrating the protocol. All
266 personnel in attendance performed the assay themselves, using saline, ethanol and silicic acid
267 anhydrate. After the workshop, the coordinators from each participating laboratory agreed to purchase
268 the cell line from RIKEN BioResource Center (Tsukuba, Japan) and to sign a memorandum pertaining
269 to borrowing the TEER recorder.

270

271 3.1.3.2 Phase 0

272 Phase 0 was designed to assess between-laboratory transferability by testing five non-coded test
273 chemicals using protocol ver. 1.30e. Each test chemical was determined to be either positive or
274 negative by obtaining consistent results from each of three runs.

275

276 3.1.3.2 Phase I

277 Phase I was designed to assess within and between-laboratory reproducibility by testing ten coded test

278 chemicals using protocol ver. 1.51e. Each test chemical was determined to be either positive or
279 negative by obtaining consistent results from each of three runs in three different sets.

280

281 3.1.3.3 Phase II

282 The original plan was split into two parts: A and B. Phase IIA was designed to assess the between-
283 laboratory reproducibility of ten coded test chemicals using protocol ver. 1.61e, after which Phase IIB
284 was to validate an additional thirty coded test chemicals using the same protocol. Phase IIB was
285 canceled when the results of Phase IIA led to a decision to undertake a major revision of protocol ver.
286 1.61e. Consequently, Phase IIA was renamed Phase II, and the planned Phase IIB was incorporated
287 into a newly designed Phase III using the protocol ver. 1.71e.

288

289 3.1.3.4 Phase III

290 Phase III was designed to assess the between-laboratory reproducibility and predictive capacity of the
291 Vitrigel-EIT method for thirty-six coded test chemicals using protocol ver. 1.71e. Each test chemical
292 was determined to be either positive or negative based on obtaining consistent results from each of
293 three runs in one set.

294

295 3.1.4 Success criteria

296 Success criteria for within and between-laboratory reproducibility was 80%. The predictive capacity
297 was assessed using thirty-six coded test chemicals. The results of statistical analysis were used to
298 determine the preliminary design for validation study as well as automatization of the test leading to
299 an increased dataset.

300 Issues related to the applicability domain were discussed by the VMT decision during assessment of
301 between-laboratory reproducibility.

302

303 3.2 Summary of protocol

304 The current test protocol is ver. 1.80e, which was designed per Yamaguchi et al., 2013, 2015 and is

305 shown in Appendix 8.2. The data sheet format is shown in Appendix 8.3.

306

307 3.2.1 Culturing HCE-T cells

308 An SV40-immortalized HCE cell strain (HCE-T cells, RCB no. 2280) was obtained from RIKEN
309 BioResource Center (Tsukuba, Japan). The cells were maintained in a culture medium comprising a
310 1:1 mixture of Dulbecco's modified eagle medium and nutrient mixture F-12 supplemented with 5%
311 heat-inactivated fetal bovine serum, 5 µg/mL recombinant human insulin, 10 ng/mL recombinant
312 human epidermal growth factor, 0.5% dimethyl sulfoxide, 100 units/mL penicillin and 100 µg/mL
313 streptomycin (Araki-Sasaki et al., 1995; Yamasaki et al., 2009). Cells were grown at 37°C in a
314 humidified atmosphere of 5% CO₂.

315

316 3.2.2 Preparation of collagen vitrigel membrane chambers

317 A collagen xerogel membrane chamber (ad-MED Vitrigel™) was purchased from Kanto Chemical
318 Co., Inc. (Tokyo, Japan). The collagen xerogel membrane chamber was set in the well of a 12-well
319 plate. Then, the collagen xerogel membrane was immersed in the culture medium by pouring 1.5 mL
320 outside and 0.5 mL inside the chamber in the well for 10 min to convert the xerogel into vitrigel
321 immediately before use.

322

323 3.2.3 Reconstruction of a human corneal epithelium model

324 The culture medium outside the chamber in the well of a 12-well plate was replaced with 1.5 mL of
325 fresh medium. The medium inside the chamber was removed and 0.5 mL of a cell suspension in a
326 culture medium at a density of 1.2×10^5 cells/mL was poured onto the CVM in the chamber and
327 cultured for 2 days at 37°C. Subsequently, the cells were cultured for 4 days at the air–liquid interface
328 to fabricate a HCE model after removing the inside medium and changing the outside medium outside
329 of the chamber. The medium outside the chamber was changed on the third day of culturing at the
330 air–liquid interface.

331

332 3.2.4 Mode of action in vivo

333 Time-dependent relative changes of TEER values after exposing chemicals to in vitro human corneal
334 epithelial models are considered to be an excellent indicator for extrapolating the destructive activity
335 of the chemicals against the barrier function of human corneal epithelium in vivo. For this reason, the
336 TEER assay is a simple and suitable method for evaluating corneal irritancy and permeability
337 quantitatively and continuously (Uematsu et al., 2007). Therefore, it is important to develop an assay
338 system that can facilitate not only the reconstruction of human corneal epithelial model but also the
339 TEER measurement and the chemical exposure.

340 Our preliminary results based on the testing of four chemicals demonstrated a correlation between
341 irritancy potential and changes in TEER. We found that non-irritants caused virtually no change in
342 TEER, moderate irritants caused only a gradual decrease of limited magnitude in TEER, and strong
343 irritants caused a rapid decrease of significant magnitude in TEER (Takezawa et al. 2011a). During
344 further testing of 30 chemicals, we consistently observed these three patterns, which we were able to
345 express mathematically using three parameters, namely, time lag, intensity, and plateau (Yamaguchi
346 et al. 2013).


347 In this study, we aimed to develop such an ideal assay method utilizing HCE-T cells and the collagen
348 vitrigel membrane chamber useful for TEER measurement.

349

350 3.2.5 Calculation of TEER values for HCE models

351 The electrical resistance of a HCE model in a CVM chamber (R_{model}) and of a blank CVM chamber
352 (R_{blank}) were measured using the TEER recorder shown in Fig. 2. The TEER value was calculated as
353 follows:

354
$$\text{TEER} = (R_{\text{model}} - R_{\text{blank}}) \times \text{effective surface area (1.0 cm}^2\text{)}$$



355

356 Fig.2. Schematic illustrations on the TEER measurement electrodes for HCE model and gross
 357 observation of TEER recorder system.

358 The electrode unit (A), the electrode unit applied for the culture media via HCE model (B) and
 359 the TEER recorder system (C).


360

361 3.2.6 Exposure to test chemicals

362 A solution of test chemical was prepared in a culture medium at a concentration of 2.5% (weight/
 363 volume), which is considered appropriate for measuring TEER values without undue influence from
 364 the electrical resistance of the test chemical itself. Test chemicals were manually mixed in the medium
 365 until the test chemical dissolves or for a maximum of one minute. If the test chemical does not
 366 dissolve readily, try using the following techniques in the following order to dissolve it: a) mix
 367 mechanically for a maximum of one minute using a vortex mixer, b) sonication for a maximum of 20
 368 minutes, or c) heating to a maximum temperature of 70°C. After trying each technique, the
 369 temperature of each test chemical solution was checked. Test chemical solution that is well
 370 dissolved or homogeneously dispersed, was moved to the next step. For test chemicals that proved to
 371 be insoluble or immiscible using the above technique, a test chemical solution was prepared as a
 372 homogeneous suspension by mixing the test chemical in the medium by vortex for up to 1 minute
 373 immediately before use (Fig.3). The pH level of each 2.5% test chemical solution was measured using
 374 universal pH test paper from ADVANTEC (Tokyo, Japan).

375 The HCE models were exposed to a test chemical on day 6, as follows: First, 500 μ L of culture

376 medium was poured in the chamber and the TEER recorder was used to obtain a pre-exposure R_{model}
 377 value for each model. Next, the medium inside the chamber was replaced with 500 μL of test chemical
 378 solution and R_{model} values were measured at intervals of 10 seconds for a period of 3 min after exposure
 379 to the test solution. Here, it is essential to obtain the reproducible data that the measurement is started
 380 within 2 to 5 seconds after adding the test chemicals. Because the liquid condition around the
 381 electrode is often unstable within 2 seconds after exposing the test chemical solution. Also, the HCE
 382 model has already been influenced with the test chemicals over 5 seconds. Three runs were made
 383 for each test chemical and a new HCE model was used in each. Test chemical exposure was conducted
 384 at an ambient temperature of $28\pm 2^\circ\text{C}$. The ambient temperature of $28\pm 2^\circ\text{C}$ for the HCE model was
 385 achieved by regulating the temperature of the 12-well plate using a hot plate, a water bath or an air
 386 conditioner. Here, it is important to confirm that the actual temperature of culture medium is $28\pm 2^\circ\text{C}$.
 387




388
 389 Fig.3. Preparation of test chemical solution per the revised protocol

390

391 3.2.7 Calculating eye irritancy of test chemicals

392 The TEER values for each test chemical were measured during the three runs and then copied to a
 393 data sheet, where eye irritancy was calculated automatically. The mean TEER values for all three tests
 394 were plotted on a time line and a profile of TEER values (dP/dT) was automatically analyzed for three
 395 parameters: time lag (t_1), intensity ($-(P_2 - P_1)/(t_2 - t_1)$), and plateau level ($100 - P_2$). Time lag (t_1) is
 396 defined as the maximum time at which a profile was maintained at $0 \geq dP/dT > -0.03\%/second$. The
 397 starting time of plateau level (t_2) after the profile was maintained at $dP/dT \leq -0.03\%/second$ for a
 398 particular period of time was defined as the initial time at which the profile was maintained at
 399 $0 \geq dP (P_3 - P_2)/dT (t_3 - t_2) > -0.03\%/s$. The time (t_3) is represented in the equation
 400 ($t_3 = t_2 + 30$ seconds) because the plateau level was evaluated by the profile for 30 seconds. P_1 , P_2 ,
 401 and P_3 are the percentages against the initial TEER value at t_1 , t_2 , and t_3 after exposure to the test
 402 chemical, as shown in Fig. 4. A score for each index was calculated using the above formula.
 403 Subsequently, the eye irritation potential of test chemicals was determined to be either irritant or non-
 404 irritant, in accordance with the criteria shown in Table 3.

405
406



407

408 Fig. 4. Schematic illustration showing an analysis of a TEER profile after exposure of a model to a
 409 test chemical.

410 t_1 represents time lag, and t_2 represents the start of the plateau level. t_3 is defined as $t_2 + 30$ s.

411 P_1 , P_2 , and P_3 indicated a percentage relative to the initial TEER value at t_1 , t_2 , and t_3 , respectively.

412
413
414

415 Table 3. Eye irritancy criteria.

Criteria	Prediction
Time lag \leq 180 or Intensity \geq 0.05 or Plateau level $>$ 5.0	Irritant (I)
Time lag $>$ 180 and Intensity $<$ 0.05 and Plateau level \leq 5.0	Non-irritant (NI)

416

417 3.2.8 Correlation with the UN GHS classification

418 The correlation with the UN GHS classification of test chemicals was estimated by calculating
419 sensitivity, specificity, and accuracy, as follows.

420
$$\text{Sensitivity (\%)} = A/(A + B) \times 100$$

421
$$\text{Specificity (\%)} = D/(C + D) \times 100$$

422
$$\text{Accuracy (\%)} = (A + D)/(A + B + C + D) \times 100$$

423 A is the number of test chemicals classified as irritants by both the traditional UN GHS classification
424 and the Vitrigel-EIT method. B is the number of test chemicals classified as irritants by the traditional
425 UN GHS classification and as non-irritants by the Vitrigel-EIT method. C is the number of test
426 chemicals classified as non-irritants by the traditional UN GHS classification and as irritants by the
427 Vitrigel-EIT method. D is the number of test chemicals classified as non-irritants by both the
428 traditional UN GHS classification and the Vitrigel-EIT method.

429

430 3.2.9 Commercial availability and/or intellectual property rights to the test method and its
431 components

432 All components and reagents using in the test method are commercially available. HCE-T cells can
433 be globally distributed from RIKEN BioResource Center. The Vitrigel-EIT method is available
434 without any restriction by its intellectual property rights. Vitrigel is registered trade mark of National
435 Agriculture and Food Research Organization (Tsukuba, Japan).

436

437 **3.3 Test chemicals**

438 3.3.1 Selection and distribution of test chemicals

439 The test chemicals were selected to ensure that a diverse range of substances were represented, and

440 aspects such as eye-irritant level per UN GHS categories, physical state, chemical class, and incidence
 441 of eye lesions were considered. Preference was given to test chemicals for which high-quality in vivo
 442 data is available, especially when the data included results from individual animals. The list includes
 443 test chemicals that were previously used in the 3-dimensional corneal model (such as EpiOcular)
 444 validation studies by EURL-ECVAM (ECETOC, 1998), the Short Time Exposure test validation
 445 study by JaCVAM and independent peer review (ICCVAM, 2010, 2013), and the OptiSafe™
 446 evaluation study by NICEATM.

447 All the test chemicals selected for this validation study are available commercially, were selected by
 448 the chemical management group, and approved by the VMT. All the test chemicals used in Phases I,
 449 II, and III were coded, and their names were provided only after completion of the study. A total of 42
 450 substances were tested by all three laboratories.

451

452 3.3.2 Test chemicals for Phases 0, I, II, and III

453 3.3.2.1 Test chemicals for Phase 0

454 Five test chemicals were selected by the VMT for use in validating between-laboratory transferability
 455 during Phase 0, as shown in Table 4. The five non-coded test chemicals were delivered to each
 456 participating laboratory by the VMT.

457

458 Table 4. List of test chemicals selected for Phase 0

No.	Test chemical	CASRN	State	Density (g/cm ³)	logP	pH	GHS
Positive control	Ethanol	64-17-5	Liquid	-0.31	7	2A	Category 1
0-1	Benzalkonium chloride	8001-54-5	Solid	0.99	1.68	7	Category 1
0-2	2-Propanol	67-63-0	Liquid	0.78	0.05	7	Category 2A
0-3	Glycerol	56-81-5	Liquid	1.26	-1.76	7	No Category
0-4	n-Hexanol	111-27-3	Liquid	0.82	2.03	7	Category 2A
0-5	Silicon dioxide n-hydrate	7699-41-4	Solid	1.58	-	7	No Category

459

460 3.3.2.2 Test chemicals for Phase I

461 Ten test chemicals were selected by the VMT for use in validating within- and between-laboratory

462 reproducibility during Phase I, as shown in Table 5. The ten test chemicals comprised five irritants
 463 and five non-irritants, five of which were solid and five of which were liquid, as shown in Table 5.
 464 To assess the within-laboratory reproducibility, the VMT selected ten test chemicals in Phase I. The
 465 VMT decided this scale based on our biostatistician's opinion about the statistical validity of the
 466 number of test chemicals used for the ECVAM validation study for skin sensitization. A detailed
 467 background is addressed at appendix 8-12. The ten test chemicals were coded and delivered in three
 468 sets to each participating laboratory by the VMT. Refer to the chemical selection report in Appendix
 469 8.4 for code numbers.
 470

Table 5. List of test chemicals selected for Phase I

No.	Test chemical	CASRN	State	Density (g/cm ³)	logP	pH	GHS
1-1	Imidazole	288-32-4	Solid	1.03	-0.08	9	Category 1
1-2	Cyclohexanol	108-93-0	Liquid	0.96	1.23	7	
1-3	3,3-Dithiodipropionic acid	1119-62-6	Solid	1.45	-0.15	4	Category 2A or 2B
1-4	Acetone	67-64-1	Liquid	0.79	-0.24	7	
1-5	3-Chloropropionitrile	542-76-7	Liquid	1.16	0.18	5	
1-6	Ammonium nitrate	6484-52-2	Solid	1.72	-	8	
1-7	n,n-Dimethylguanidine sulfate	598-65-2	Solid	-	-	7	No Category
1-8	Toluene	108-88-3	Liquid	0.87	2.73	7	
1-9	3-Methoxy-1,2-propanediol	623-39-2	Liquid	1.11	-1.13	7	
1-10	Gluconolactone	90-80-2	Solid	1.61	-2.48	6	

471

472 3.3.2.3 Test chemicals for Phase II

473 Ten test chemicals were selected by the VMT for use in validating between-
 474 laboratory reproducibility during Phase II, as shown in Table 6. The ten test
 475 chemicals comprised four classified UN GHS Category 1, three classified UN GHS
 476 Category 2A or 2B, and three classified UN GHS No Category, five of which were

477 solids and five of which were liquid, as listed in Table 6. The ten test chemicals were
 478 coded and delivered in one set to each participating laboratory by the VMT. Refer to
 479 the chemical selection report in Appendix 8.4 for code numbers.

480

481 Table 6. List of test chemicals selected for Phase II

No.	Test chemical	CASRN	State	Density (g/cm ³)	logP	pH	GHS
2-1	Imidazole	288-32-4	Solid	1.03	-0.08	9	Category 1
2-2	Cyclohexanol	108-93-0	Liquid	0.96	1.23	7	
2-3	Sodium dodecyl sulfate	151-21-3	Solid	0.40	1.60	7	
2-4	Sodium salicylate	54-21-7	Solid	0.32	0.42	7	
2-5	Cyclopentanol	96-41-3	Liquid	0.95	2.41	7	Category 2A or 2B
2-6	2-Methyl-1-pentanol	105-30-6	Liquid	0.83	1.76	7	
2-7	α -Hexylcinnamaldehyde	101-86-0	Liquid	0.95	5.12	7	
2-8	n,n-Dimethylguanidine sulfate	598-65-2	Solid	-	-	7	No Category
2-9	Toluene	108-88-3	Liquid	0.87	2.73	7	
2-10	Gluconolactone	90-80-2	Solid	1.61	-2.48	6	

482

483 3.3.2.4 Test chemicals for Phase III

484 Thirty-six test chemicals were selected by the VMT for use in validating between-laboratory
 485 reproducibility and predictive capacity during Phase III, as shown in Table 7. The number of chemicals,
 486 total 36 chemicals, was decided in consideration of Kanto Chemical's ability to supply the CVM
 487 chambers as well as the participating laboratories' testing capacity. All test chemicals were selected to
 488 ensure that a diverse range of substances were represented, and aspects such as eye-irritant level per
 489 UN GHS categories, physical state, chemical class, and incidence of eye lesions were considered.
 490 Preference was given to test chemicals for which high-quality in vivo data is available, especially
 491 when the data included results from individual animals. The number of test chemicals in each GHS
 492 classification is shown in Table 8. The number of solid and liquid test chemicals is show in Table 9.
 493 The thirty-six test chemicals were coded and delivered in one set to each participating laboratory by

494 the VMT. Refer to the chemical selection report in Appendix 8.4 for code numbers.

495 The chemical master at Lab C revealed the name of test chemical No. 3-16, sodium chloroacetate,
 496 which was subsequently eliminated from the list and cyclopentanol was delivered by the VMT as an
 497 alternative.

498

Table 7. List of test chemicals selected for Phase III

No.	Test chemical	CASRN	State	Density (g/cm ³)	logP	pH	GHS
3-1	2,5-Dimethyl-2,5-hexanediol	110-03-2	Solid	0.90	1.19	7	Category 1
3-2	2-Benzyl-4-chlorophenol	120-32-1	Solid	1.19	3.60	7	
3-3	2,2-Dimethyl butanoic acid	595-379	Liquid	0.93	1.90	4	
3-4	Captan	133-06-2	Solid	1.74	2.80	7	
3-5	Tetra-n-octylammonium bromide	14866-33-2	Solid	0.94	3.45	7	
3-6	Butanol	71-36-3	Liquid	0.81	0.88	8	
3-7	3-(2-Aminoethylamino) propyl]trimethoxysilane	1760-24-3	Liquid	1.01	-1.00	10	
3-8	Sodium dodecyl sulfate	151-21-3	Solid	0.40	1.60	7	
3-9	m-Phenylenediamine	108-45-2	Solid	1.14	-0.33	8	
3-10	Tetraethylene glycol	17831-71-9	Liquid	1.13	1.26	7	
3-30	Imidazole	288-32-4	Solid	1.03	-0.08	9	Category 2A or 2B
3-32	Sodium salicylate	54-21-7	Solid	0.32	0.42	7	
3-11	gamma-Butyrolactone	96-48-0	Liquid	1.13	-0.64	7	
3-12	Methyl acetate	79-20-9	Liquid	0.93	0.18	7	
3-13	Myristyl alcohol	112-72-1	Solid	0.82	6.03	7	
3-14	2,6-Dichlorobenzoyl chloride	4659-45-4	Liquid	1.47	2.54	3	
3-15	Dibenzyl phosphate	1623-08-1	Solid	1.46	1.71	3	
3-17	1-(2-Propoxy-1-methylethoxy)-2-propanol	29911-27-1	Liquid	0.94	1.14	7	
3-18	Camphene	79-92-5	Solid	0.84	1.94	7	
3-19	Ethyl-2-methylacetoacetate	609-14-3	Liquid	1.00	0.78	7	
3-20	Propylene glycol propyl ether	1569-01-3	Liquid	0.89	0.56	8	No Category
3-31	2-Methyl-1-pentanol	105-30-6	Liquid	0.83	1.76	7	
3-33	α -Hexylcinnamaldehyde	101-86-0	Liquid	0.95	5.12	7	
3-37	Cyclopentanol	96-41-3	Liquid	0.95	2.41	7	
3-21	Methyl amyl ketone	110-43-0	Liquid	0.82	1.98	7	No Category
3-22	2-(n-Dodecylthio)ethanol	1462-55-1	Liquid	0.91	-	7	
3-23	iso-Octylthioglycolate	25103-09-7	Liquid	0.97	4.36	7	
3-24	2,4-Difluoronitrobenzene	446-35-5	Liquid	1.46	-1.18	7	

3-25	tetra-Aminopyrimidine sulfate	5392-28-9	Solid	1.65	0.27	3
3-26	2,4-Pentanediol	625-69-4	Liquid	0.96	0.35	8
3-27	iso-Octyl acrylate	29590-42-9	Liquid	0.88	4.61	7
3-28	Silicon dioxide n-hydrate	7699-41-4	Solid	1.58	-	7
3-29	Potassium tetrafluoroborate	14075-53-7	Solid	2.51	-	7
3-34	n,n-Dimethylguanidine sulfate	598-65-2	Solid	-	-	7
3-35	Toluene	108-88-3	Liquid	0.87	2.73	7
3-36	Gluconolactone	90-80-2	Solid	1.61	-2.48	6

499

500 Table 8. Breakdown of test chemicals used in Phase III

GHS				Total
Category 1	Category 2A/2B	Category 2B	No Category	
12	8	4	12	36

501

502 Table 9. Breakdown of test chemicals used in Phase III per physical state

Solid	Liquid	Total
16	20	36

503

504 3.4 Quality assurance

505 All testing at the participating laboratories was conducted in accordance with the principles of Good
506 Laboratory Practice (GLP, OECD 1998), and were well documented, including a discussion of any
507 impact on study results. Records were kept of the maintenance of measuring instruments, the
508 production of HCE models, and the preparation and application of test chemicals using a format
509 prepared by the lead laboratory. The data was input using a format developed for this validation study
510 by the lead laboratory and the biostatistician. Personnel at the participating laboratories recorded the
511 necessary information, including the code names of each test chemical, names and date of preparation
512 of solvents, degree of solubility or suspensibility, and concentration of the test solution. These records
513 were sent from the participating laboratories to JaCVAM, where they were checked for validity and
514 accuracy as well as archived.

515

516 3.5 Record collection and analysis

517 Data collection and analysis were performed in close collaboration with biostatisticians and the quality

518 assurance group. Independent biostatisticians collected and organized data as shown in Appendix 8.5
519 using custom data collection software, and all records were checked by the quality assurance group.
520 Any concerns at the participating laboratories over record keeping were resolved by the on-site study
521 director and reported at VMT meetings.

522 At the final VMT meeting, all data was finalized and decoded by the trial coordinator, after which the
523 biostatisticians performed a statistical analysis. Data management procedures and statistical tools were
524 approved by the trial coordinator and the data analysis group. Any deviation found in the analysis was
525 well documented, including a discussion of any impact on study results. Test results were evaluated
526 for correlation with UN GHS classification based on predetermined criteria.

527 Predictive capacity of the Vitrigel-EIT method was evaluated using data from Phase III. First, an
528 analysis was performed to assess predictive capacity in accordance with UN GHS classification per
529 either a bottom-up or a top-down approach (Scott, 2010). Further analysis was then performed to
530 reduce false negatives by limiting the scope of the applicability domain.

531

532 **4 Results**

533 All data were analyzed by biostatisticians as shown in Appendix 8.5. The quality assurance group
534 checked all records, following the quality assurance protocol, as summarized in Appendix 8.6.

535 **4.1 Study duration**

536 Phase 0 was conducted from June to December 2013, using protocol ver. 1.30e.

537 Phase I was conducted from March to April 2014, using protocol ver. 1.51e.

538 Phase II was conducted from June to September 2014, using protocol ver. 1.61e.

539 Phase III was conducted from November 2014 to January 2015, using protocol ver. 1.71e.

540 VMT meetings were held during the intervals between these phases. The minutes of the VMT
541 meetings are show in Appendix 8.7.

542

543 4.1.1 Phase 0

544 Phase 0 was designed to assess between-laboratory transferability by testing five non-coded test

545 chemicals using protocol ver. 1.30e.

546 Although the results were generally good, two issues were identified: the results for glycerol obtained
547 at BRC were inconsistent, and those for ethanol (positive control) obtained at Daicel did not meet the
548 success criteria for between-laboratory reproducibility shown in Tables 10 and 11. With the exception
549 of the results for glycerol obtained at BRC, the data was overall highly consistent. The results for two
550 of the three runs of ethanol at Daicel fell below the acceptance criteria for positive control (plateau
551 level: 20 to 30%) in Fig.5. At the 1st VMT meeting, members discussed a proposal to use
552 benzalkonium chloride as the positive control instead of ethanol, in order to ensure clear and consistent
553 results. Ultimately, ethanol was used as a reference control, and its range was modified to 15–30% at
554 plateau level. This exact range was to be finalized based on the results of Phase I.

555 The VMT requested additional testing at BRC and Daicel using a revised protocol, ver. 1.40e. After
556 confirming the results of the additional testing (data not shown), all VMT members agreed to proceed
557 with Phase I. The following key issues were addressed by revising the protocol to ver. 1.51e prior to
558 the start of Phase I.

- 559 • Success criteria for the reference control: Range at plateau level of 10–30%
- 560 • Ambient temperature during TEER measurement: 18–30°C
- 561 • Time from start of exposure to start of measurement: within 2 seconds

562 Table 10-1. Data for Phase 0, Trial 1

No.	Test chemical	FDSC				BRC				Daicel			
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.03 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI
	Positive control (ethanol)	20 (I)	0.13 (I)	23 (I)	I	0 (I)	0.11 (I)	21 (I)	I	10 (I)	0.09 (I)	18 (NI)	N
0-1	Benzalkonium chloride	0 (I)	0.32 (I)	58 (I)	I	0 (I)	0.30 (I)	54 (I)	I	0 (I)	0.21 (I)	37 (I)	I
0-2	2-Propanol	10 (I)	0.17 (I)	32 (I)	I	0 (I)	0.16 (I)	29 (I)	I	10 (I)	0.13 (I)	24 (I)	I
0-3	Glycerol	0 (I)	0.31 (I)	22 (I)	I	10 (I)	0.12 (I)	4 (NI)	I	0 (I)	0.25 (I)	13 (I)	I
0-4	n-Hexanol	0 (I)	0.21 (I)	38 (I)	I	30 (I)	0.14 (I)	23 (I)	I	10 (I)	0.15 (I)	27 (I)	I
0-5	Silicon dioxide n-hydrate	190 (NI)	-0.02 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI

563

564

565 Table 10-2. Data for Phase 0, Trial 2

No.	Test chemical	FDSC				BRC				Daicel			
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.02 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI
	Positive control (ethanol)	10 (I)	0.12 (I)	22 (I)	I	0 (I)	0.12 (I)	21 (I)	I	10 (I)	0.13 (I)	24 (I)	I
0-1	Benzalkonium chloride	0 (I)	0.32 (I)	57 (I)	I	0 (I)	0.30 (I)	54 (I)	I	0 (I)	0.33 (I)	60 (I)	I
0-2	2-Propanol	0 (I)	0.13 (I)	24 (I)	I	0 (I)	0.18 (I)	32 (I)	I	10 (I)	0.13 (I)	24 (I)	I
0-3	Glycerol	0 (I)	0.31 (I)	12 (I)	I	190 (NI)	-0.10 (NI)	2 (NI)	NI	0 (I)	0.21 (I)	12 (I)	I
0-4	n-Hexanol	10 (I)	0.15 (I)	28 (I)	I	0 (I)	0.21 (I)	37 (I)	I	40 (I)	0.11 (I)	19 (I)	I
0-5	Silicon dioxide n-hydrate	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	0.00 (NI)	0 (NI)	NI

566

567 Table 10-3. Data for Phase 0, Trial 3

No.	Test chemical	FDSC				BRC				Daicel			
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.10 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI
	Positive control (ethanol)	20 (I)	0.12 (I)	22 (I)	I	0 (I)	0.14 (I)	21 (I)	I	10 (I)	0.10 (I)	19 (NI)	NI
0-1	Benzalkonium chloride	0 (I)	0.34 (I)	62 (I)	I	0 (I)	0.29 (I)	52 (I)	I	0 (I)	0.30 (I)	55 (I)	I
0-2	2-Propanol	10 (I)	0.15 (I)	29 (I)	I	0 (I)	0.16 (I)	29 (I)	I	10 (I)	0.13 (I)	24 (I)	I
0-3	Glycerol	0 (I)	0.30 (I)	18 (I)	I	0 (I)	0.41 (I)	16 (I)	I	0 (I)	0.19 (I)	13 (I)	I
0-4	n-Hexanol	0 (I)	0.22 (I)	39 (I)	I	0 (I)	0.16 (I)	28 (I)	I	20 (I)	0.15 (I)	27 (I)	I
0-5	Silicon dioxide n-hydrate	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.04 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI

568


569

570 Table 11. Combined results for Phase 0

No.	Test chemical	FDSC			BRC			Daicel		
		1	2	3	1	2	3	1	2	3
	Negative control	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass
	Positive control (ethanol)	Pass	Pass	Pass	Pass	Pass	Pass	NG	Pass	NG
0-1	Benzalkonium chloride	I	I	I	I	I	I	I	I	I
0-2	2-Propanol	I	I	I	I	I	I	I	I	I
0-3	Glycerol	I	I	I	I	NI	I	I	I	I
0-4	n-Hexanol	I	I	I	I	I	I	I	I	I
0-5	Silicon dioxide n-hydrate	NI	NI	NI	NI	NI	NI	NI	NI	NI

571

572



573

574 Fig. 5. Distribution of the three trials of Phase 0

575

576 4.1.2 Phase I

577 Phase I was designed to assess within and between-laboratory reproducibility by testing ten coded test
 578 chemicals using protocol ver. 1.51e.

579 The results for two of nine runs of the reference control (ethanol) at FDSC did not initially meet the
 580 success criteria, but were successfully retested, as shown in Tables 12 and 13. Analysis of Phase 0 and

581 Phase I results as well as concerns for quality assurance of the HCE models led the VMT to include
 582 success criteria for the reference control in the next version of the test protocol. Consequently, the

583 VMT recommended that the range for the reference control should be revised, so expanded success
 584 criteria for the positive and reference controls were developed by the lead laboratory. Furthermore,

585 the results for test chemical No. 1-7, n,n-dimethyl guanidine sulfate, and No. 1-10, gluconolactone at
 586 FDSC as well as for test chemical No. 1-8, toluene, at Daicel failed to satisfy the success criteria for

587 the within-laboratory reproducibility, as shown in Tables 12 and 14. All results at BRC met the success
 588 criteria. Thus, the within-laboratory reproducibility was 80% at FDSC, 90% at Daicel, and 100% at

589 BRC, which was sufficient to satisfy the success criteria of 80% as stated in the study plan. Although
 590 the results for No. 1-1, imidazole, and No. 1-8, toluene, were somewhat inconsistent, the data showed

591 a between-laboratory reproducibility of 80%, which met the acceptance criteria of 80% as stated in
 592 the study plan. The following key issues were addressed by revising the protocol to ver. 1.61e prior to

593 the start of Phase II.

- 594 · Revised the term “room temperature” to read “ambient temperature for the experiment,”
595 because control of ambient temperature is necessary.
- 596 · Included success criteria for the reference control and changed the phrase “Plateau level is
597 between 10% and 30%, inclusive” to “Plateau level is between 10% and 40%, inclusive”.
- 598 · Change the ambient temperature for TEER measurement from “between 18 and 30°C” to
599 “between 22 and 30°C,” because temperature of the HCE model can affect TEER.
- 600 · Changed the description of the procedure for preparing test chemical solutions
- 601 Old: If the test chemical has not been dissolved, try to dissolve it by the mechanical mixture
602 for a maximum 1-minute period using a vortex, by the sonication for a maximum 20-minute
603 period, or by the heating to 70°.
- 604 New: If the test chemical does not dissolve readily, try one of the following techniques: a) mix
605 mechanically for a maximum of one minute using a vortex mixer, b) sonication for a
606 maximum of 20 minutes, or c) heating to a maximum temperature of 70°C.
- 607 This was done, because some personnel at the participating laboratories misunderstood the
608 procedure during Phase 1 and thought that all three of these techniques should be performed.
609 Also, the term “vortex” was corrected to “vortex mixer.”
- 610 · Added a precaution to seal the 15-mL tube tightly during testing to prevent volatilization of
611 the test chemical solutions, as follows: “To prevent volatilization of test chemical solutions,
612 the 15-mL tube should be sealed tightly after weighing test chemicals, except when adding
613 culture medium and sampling the 2.5% test chemical solution.”
- 614 · Added instructions to reject and retest any result in which there is a significant discrepancy
615 between the initial TEER value and the TEER value measured at 0 seconds, which would
616 indicate some technical issue, such as electrical noise or improper use of electrode, as follows:
617 “If there is a discrepancy of 40 $\Omega \cdot \text{cm}^2$ or more between the initial TEER value and the TEER
618 value measured at 0 seconds, reject the test results and retest using another HCE model.”

619 Table 12-1. Data for Phase I, Trial 1

No.	Test chemical	FDSC				BRC				Daicel			
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.02 (NI)	0 (NI)	NI	190 (NI)	-0.04 (NI)	0 (NI)	NI	190 (NI)	-0.02 (NI)	0 (NI)	NI
	Positive control	0 (I)	0.35 (I)	64 (I)	I	0 (I)	0.39 (I)	51 (I)	I	0 (I)	0.35 (I)	64 (I)	I
	Reference control	20 (I)	0.09 (I)	16 (I)	I	0 (I)	0.18 (I)	16 (I)	I	10 (I)	0.14 (I)	26 (I)	I
1-1	Imidazole	190 (NI)	0.00 (NI)	0 (NI)	NI	120 (I)	0.15 (I)	11 (I)	I	130 (I)	0.12 (I)	9 (I)	I
1-2	Cyclohexanol	10 (I)	0.23 (I)	42 (I)	I	0 (I)	0.21 (I)	37 (I)	I	0 (I)	0.29 (I)	51 (I)	I
1-3	3,3-Dithiodipropionic acid	190 (NI)	-0.12 (NI)	0 (NI)	NI	190 (NI)	-0.07 (NI)	0 (NI)	NI	190 (NI)	-0.06 (NI)	0 (NI)	NI
1-4	Acetone	30 (I)	0.08 (I)	15 (I)	I	10 (I)	0.07 (I)	6 (I)	I	0 (I)	0.16 (I)	28 (I)	I
1-5	3-Chloropropionitrile	10 (I)	0.18 (I)	32 (I)	I	10 (I)	0.12 (I)	22 (I)	I	20 (I)	0.22 (I)	38 (I)	I
1-6	Ammonium nitrate	0 (I)	0.77 (I)	54 (I)	I	0 (I)	1.36 (I)	27 (I)	I	0 (I)	0.79 (I)	48 (I)	I
1-7	n,n-Dimethylguanidine sulfate	0 (I)	0.40 (I)	32 (I)	I	0 (I)	0.37 (I)	7 (I)	I	0 (I)	0.44 (I)	26 (I)	I
1-8	Toluene	190 (NI)	0.01 (NI)	0 (NI)	NI	170 (I)	0.02 (NI)	1 (NI)	I	190 (NI)	0.02 (NI)	1 (NI)	NI
1-9	3-Methoxy-1,2-propanediol	190 (NI)	-0.07 (NI)	0 (NI)	NI	190 (NI)	-0.08 (NI)	0 (NI)	NI	190 (NI)	-0.12 (NI)	0 (NI)	NI
1-10	Gluconolactone	0 (I)	0.21 (I)	11 (I)	I	0 (I)	0.34 (I)	3 (NI)	I	0 (I)	0.22 (I)	9 (I)	I

620

621 Table 12-2. Data for Phase I, Trial 2

No.	Test chemical	FDSC				BRC				Daicel			
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	0.00 (NI)	0 (NI)	NI	190 (NI)	-0.03 (NI)	0 (NI)	NI	190 (NI)	-0.04 (NI)	0 (NI)	NI
	Positive control	0 (I)	0.33 (I)	59 (I)	I	0 (I)	0.23 (I)	42 (I)	I	0 (I)	0.42 (I)	75 (I)	I
	Reference control	20 (I)	-	3 (NI)	NG	0 (I)	0.12 (I)	21 (I)	I	0 (I)	0.17 (I)	30 (I)	I
1-1	Imidazole	190 (NI)	-0.03 (NI)	0 (NI)	NI	160 (I)	0.13 (I)	4 (NI)	I	140 (I)	0.11 (I)	7 (I)	I
1-2	Cyclohexanol	30 (I)	0.16 (I)	25 (I)	I	0 (I)	0.40 (I)	48 (I)	I	0 (I)	0.34 (I)	51 (I)	I
1-3	3,3-Dithiodipropionic acid	190 (NI)	-0.06 (NI)	0 (NI)	NI	190 (NI)	-0.07 (NI)	0 (NI)	NI	190 (NI)	-0.05 (NI)	0 (NI)	NI
1-4	Acetone	10 (I)	0.04 (NI)	10 (I)	I	0 (I)	0.12 (I)	21 (I)	I	0 (I)	0.17 (I)	30 (I)	I
1-5	3-Chloropropionitrile	90 (I)	0.19 (I)	20 (I)	I	10 (I)	0.20 (I)	36 (I)	I	10 (I)	0.21 (I)	39 (I)	I
1-6	Ammonium nitrate	0 (I)	0.69 (I)	21 (I)	I	0 (I)	0.67 (I)	27 (I)	I	0 (I)	1.05 (I)	52 (I)	I
1-7	n,n-Dimethylguanidine sulfate	190 (NI)	-0.05 (NI)	2 (NI)	NI	0 (I)	0.53 (I)	21 (I)	I	0 (I)	0.54 (I)	27 (I)	I
1-8	Toluene	190 (NI)	-0.01 (NI)	0 (NI)	NI	150 (I)	0.02 (NI)	1 (NI)	I	190 (NI)	0.00 (NI)	0 (NI)	NI
1-9	3-Methoxy-1,2-propanediol	190 (NI)	-0.05 (NI)	0 (NI)	NI	190 (NI)	-0.12 (NI)	0 (NI)	NI	190 (NI)	-0.11 (NI)	0 (NI)	NI
1-10	Gluconolactone	190 (NI)	-0.04 (NI)	0 (NI)	NI	0 (I)	0.28 (I)	8 (I)	I	10 (I)	0.18 (I)	10 (I)	I

622 Table 12-3. Data for Phase I, Trial 3

No.	Test chemical	FDSC				BRC				Daicel			
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.02 (NI)	0 (NI)	NI	190 (NI)	-0.02 (NI)	0 (NI)	NI	190 (NI)	-0.04 (NI)	0 (NI)	NI
	Positive control	0 (I)	0.36 (I)	65 (I)	I	0 (I)	0.31 (I)	55 (I)	I	0 (I)	0.37 (I)	66 (I)	I
	Reference control	0 (I)	0.18 (I)	33 (I)	NG	0 (I)	0.12 (I)	22 (I)	I	10 (I)	0.15 (I)	27 (I)	I
1-1	Imidazole	190 (NI)	-0.01 (NI)	0 (NI)	NI	110 (I)	0.17 (I)	13 (I)	I	60 (I)	0.14 (I)	20 (I)	I
1-2	Cyclohexanol	0 (I)	0.26 (I)	46 (I)	I	0 (I)	0.27 (I)	48 (I)	I	0 (I)	0.33 (I)	59 (I)	I
1-3	3,3-Dithiodipropionic acid	190 (NI)	-0.05 (NI)	0 (NI)	NI	190 (NI)	-0.08 (NI)	0 (NI)	NI	190 (NI)	-0.0 (NI)	0 (NI)	NI
1-4	Acetone	10 (I)	0.10 (I)	19 (I)	I	0 (I)	0.20 (I)	36 (I)	I	0 (I)	0.18 (I)	32 (I)	I
1-5	3-Chloropropionitrile	10 (I)	0.22 (I)	39 (I)	I	20 (I)	0.12 (I)	22 (I)	I	10 (I)	0.25 (I)	44 (I)	I
1-6	Ammonium nitrate	0 (I)	0.62 (I)	37 (I)	I	0 (I)	0.25 (I)	50 (I)	I	0 (I)	0.94 (I)	47 (I)	I
1-7	n,n-Dimethylguanidine sulfate	0 (I)	0.36 (I)	25 (I)	I	0 (I)	0.45 (I)	23 (I)	I	0 (I)	0.46 (I)	27 (I)	I
1-8	Toluene	190 (NI)	-0.03 (NI)	0 (NI)	NI	80 (I)	0.05 (I)	8 (I)	I	130 (I)	0.03 (NI)	2 (I)	I
1-9	3-Methoxy-1,2-propanediol	190 (NI)	-0.09 (NI)	0 (NI)	NI	190 (NI)	-0.12 (NI)	0 (NI)	NI	190 (NI)	-0.11 (NI)	0 (NI)	NI
1-10	Gluconolactone	10 (I)	0.10 (I)	5 (I)	I	0 (I)	0.30 (I)	9 (I)	I	10 (I)	0.18 (I)	10 (I)	I
	Reference control (2)	10 (I)	0.12 (I)	22 (I)	I	-	-	-	-	-	-	-	-

623

624 Table 13. Combined results for Phase I control chemicals

	FDSC			BRC			Daicel		
	1	2	3	1	2	3	1	2	3
Negative control	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass
Positive control	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass
Reference	Pass	NG	NG	Pass	Pass	Pass	Pass	Pass	Pass
Reference (2)			Pass						

625

626

627 Table 14. Combined results for Phase I test chemicals

GHS	No.	Test chemical	FDSC			BRC			Daicel		
			1	2	3	1	2	3	1	2	3
Cat.1	1-1	Imidazole	NI	NI	NI	I	I	I	I	I	I
	1-2	Cyclohexanol	I	I	I	I	I	I	I	I	I
Cat. 2A & 2B	1-3	3,3-Dithiodipropionic acid	NI	NI	NI	NI	NI	NI	NI	NI	NI
	1-4	Acetone	I	I	I	I	I	I	I	I	I
	1-5	3-Chloropropionitrile	I	I	I	I	I	I	I	I	I
	1-6	Ammonium nitrate	I	I	I	I	I	I	I	I	I
No Category (NC)	1-7	n,n-Dimethylguanidine sulfate	I	NI	I	I	I	I	I	I	I
	1-8	Toluene	NI	NI	NI	I	I	I	NI	NI	I
	1-9	3-Methoxy-1,2-propanediol	NI	NI	NI	NI	NI	NI	NI	NI	NI
	1-10	Gluconolactone	I	NI	I	I	I	I	I	I	I

628

629

630

631 4.1.3 Phase II

632 Phase II was designed to assess the between-laboratory reproducibility of ten coded test chemicals
633 using protocol ver. 1.61e.

634 Results for two of the ten test chemicals failed to satisfy the success criteria for between-laboratory
635 reproducibility: No. 2-1, imidazole, and No. 2-9, toluene, as shown in Tables 15, 16, and 17. Although
636 the concordance was 80% between the three laboratories, which was sufficient to satisfy the success
637 criteria, the VMT was concerned over the failure to properly identify No. 2-1, imidazole, which is a
638 UN GHS category 1 irritant. Therefore, the VMT was unanimous in recognizing the need to clarify
639 the reason for this failure.

640 During a VMT teleconference to discuss the results of Phase II, the lead laboratory suggested that it
641 might be necessary to control the ambient temperature at which tests were conducted. The lead
642 laboratory had obtained data at the relatively high ambient temperature of 28°C. In addition, the time
643 dependent TEER profile after exposing imidazole was affected by the temperature. In case the
644 temperature below 22°C, imidazole was classified as non-irritant. All laboratories performed
645 additional testing of No. 2-1, imidazole, under the modified parameters given in Fig.6 and as shown
646 in Table 18. All laboratories correctly identified No. 2-1, imidazole, as an irritant, which suggested the
647 need for rigorous control of the ambient temperature, and led to a major revision of the protocol prior
648 to Phase III.

649 Due to this revision, the VMT recognized that Phase II data should not be combined with Phase III
650 data to assess predictive capacity and decided to undertake validation of between-laboratory
651 reproducibility and predictive capacity in Phase III using revised protocol ver. 1.71e. In consideration
652 of the capacity of the participating laboratories, the number of test chemicals for Phase III was reduced
653 from 40 in Phases IIA and IIB of the original study plan to just 36. Thus, a total of four chemicals (two
654 from UN GHS category 1, 1 from UN GHS category 2, and 1 No Category) were removed from the
655 original list of test chemicals.

656 The following key issues were addressed by revising the protocol to ver. 1.71e prior to the start of
657 Phase III.

- 658 • Having recognized the need to control ambient temperature, we replaced the instruction “Let
659 stand for 10 minutes (within 2 hours) at the ambient temperature for the experiment” to
660 “Adjust the temperature of the model to $28\pm 2^{\circ}\text{C}$.”
- 661 • Replaced all instances of the phrase “ambient temperature for the experiment” to “between
662 22 and 30°C .”
- 663 • Changed the success criteria for the reference control from “Plateau level is between 10%
664 and 30%, inclusive” to “Plateau level is 10% or more.” The upper limit for this success
665 criterion will be determined after reviewing the results of Phase III.
- 666

667 Table 15. Data for Phase II

No.	Test chemical	FDSC				BRC				Daicel			
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.04 (NI)	0 (NI)	NI	190 (NI)	-0.08 (NI)	0 (NI)	NI	190 (NI)	-0.02 (NI)	0 (NI)	NI
	Positive control	0 (I)	0.41 (I)	74 (I)	I	0 (I)	0.33 (I)	59 (I)	I	0 (I)	0.30 (I)	54 (I)	I
	Reference control	0 (I)	0.24 (I)	31 (I)	I	0 (I)	0.14 (I)	25 (I)	I	0 (I)	0.16 (I)	24 (I)	I
2-1	Imidazole	190 (NI)	0.00 (NI)	3 (NI)	NI	140 (I)	0.15 (I)	8 (I)	I	190 (NI)	0.00 (NI)	0 (NI)	NI
2-2	Cyclohexanol	0 (I)	0.51 (I)	51 (I)	I	0 (I)	0.32 (I)	48 (I)	I	0 (I)	0.25 (I)	38 (I)	I
2-3	Sodium dodecyl sulfate	0 (I)	0.41 (I)	74 (I)	I	0 (I)	0.32 (I)	58 (I)	I	0 (I)	0.31 (I)	56 (I)	I
2-4	Sodium salicylate	0 (I)	0.80 (I)	48 (I)	I	0 (I)	0.41 (I)	33 (I)	I	0 (I)	0.54 (I)	33 (I)	I
2-5	Cyclopentanol	0 (I)	0.28 (I)	39 (I)	I	0 (I)	0.22 (I)	40 (I)	I	0 (I)	0.17 (I)	30 (I)	I
2-6	2-Methyl-1-pentanol	0 (I)	0.30 (I)	54 (I)	I	0 (I)	0.23 (I)	35 (I)	I	10 (I)	0.14 (I)	26 (I)	I
2-7	α -Hexylcinnamaldehyde	190 (NI)	-0.03 (I)	0 (NI)	NI	190 (NI)	-0.03 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI
2-8	n,n-Dimethylguanidine sulfate	0 (I)	0.83 (I)	42 (NI)	I	0 (I)	0.37 (I)	26 (I)	I	0 (I)	0.54 (I)	27 (I)	I
2-9	Toluene	60 (I)	0.06 (I)	9 (I)	I	190 (NI)	0.00 (NI)	0 (NI)	NI	190 (NI)	-0.02 (NI)	0 (NI)	NI
2-10	Gluconolactone	0 (I)	0.48 (I)	19 (I)	I	0 (I)	0.30 (I)	12 (I)	I	0 (I)	0.23 (I)	9 (I)	I

668

669 Table 16. Results for Phase II control chemicals

	FDSC	BRC	Daicel
Negative control	Pass	Pass	Pass
Positive control	Pass	Pass	Pass
Reference	Pass	Pass	Pass

670

671

672 Table 17. Results for Phase II test chemicals

GHS	No.	Test chemical	FDSC	BRC	Daicel
Cat. 1	2-1	Imidazole	NI	I	NI
	2-2	Cyclohexanol	I	I	I
	2-3	Sodium dodecyl sulfate	I	I	I
	2-4	Sodium salicylate	I	I	I
Cat. 2A & 2B	2-5	Cyclopentanol	I	I	I
	2-6	2-Methyl-1-pentanol	I	I	I
	2-7	α -Hexylcinnamaldehyde	NI	NI	NI
No Category	2-8	n,n-Dimethylguanidine sulfate	I	I	I
	2-9	Toluene	I	NI	NI
	2-10	Gluconolactone	I	I	I

673


674

675 Table 18. List of test conditions at each lab.


	Phase II study			Additional		
	Circumstances	Part measured	Temp. (°C)	Circumstances	Part measured	Temp. (°C)
FDSC	Room temp.	Room temp.	24-26	On hot plate	Medium at a well	27-28
BRC	Room temp.	Room temp.	22-25	In Water bath	Medium at a well	27.4-28.6
Daicel	Room temp.	Room temp.	22	Room temp.	Room temp.	28±2
Lead Lab	Room temp.	Medium at a well	28			

676


677



678



679



680

Fig.6. Additional data of Imidazole on Vitrigel-EIT phase II study

681

682 4.1.4 Phase III

683 During Phase III, the VMT received a question about test chemical No. 3-16, sodium chloroacetate,
684 from the on-site study director at Daicel, who opened the MSDS due to concerns over legal
685 compliance in handling deleterious substances. After considering the possibility of using this chemical,
686 the VMT decided instead to delete it from the list of test chemicals, and in its place, distributed to all
687 laboratories a new test chemical: No. 3-37, cyclopentanol. This test chemical is a UN GHS category
688 2B substance, just like No. 3-16, sodium chloroacetate.

689 There were some discrepancies in the Phase III results that can be attributed to differences the
690 techniques used to dissolve the test chemicals. To resolve this issue, the protocol was revised to
691 ver. 1.80e by limiting the techniques to be used to dissolve test chemicals.

692 Also, an additional procedure was included, which calls for the pH level of each 2.5% test chemical
693 solution to be measured using universal pH test paper to ensure that the test chemical falls within the
694 applicability domain.

695

696 Other procedural inconsistencies that require further study to determine whether or not standardization
697 is necessary include the following.

698 a. The time interval from the start of exposure to a test chemical until the start of TEER
699 measurement: 4 s at FDSC, 3 s at BRC, and 2 s at Daicel

700 b. Temperature of the models: 27.0–28.7°C in culture medium at FDSC, 26.4–28.0°C in a water
701 bath at BRC, and 26.9–28.4°C in culture medium at Daicel

702 c. Number of insoluble test chemicals: Of the 21 test chemical solutions prepared at FDSC, four
703 exhibited sediment and two exhibited supernatants (Nos. 212, 216); of the 19 test chemicals
704 prepared at BRC, 10 exhibited sediment and seven exhibited supernatants (Nos. 213, 221,
705 222, 223, 232, 234, and 236); and of the 17 test chemicals prepared at Daicel, seven exhibited
706 sediment and 10 exhibited supernatant (Nos. 202, 210, 218, 219, 220, 224, 230, 231, 233,
707 and 235).

708 d. Other issues:

709 At Daicel, different batches of the frozen cell lines were used.

710 At FDSC, test chemical No. 216 was tested twice, but the data was not approved due to and
711 inappropriate procedure.

712

713 All of the aforementioned issues were reported to the VMT, which unanimously agreed that these
714 were minor issues that did not impact data analysis.

715 In Tables 19, 20, and 21, the between-laboratory reproducibility was 92% (33/36), which met the
716 acceptance criteria of 80%. The results of a few insoluble test chemicals were inconsistent between
717 the laboratories, including No. 3-5, tetra-N-octylammonium bromide, No. 3-14, 2,6-dichlorobenzyl
718 chloride, and No. 3-18, camphene, and the VMT discussed the difficulties inherent in assessing these
719 substances due to low solubility in the culture medium.

720 The following key issues were addressed by revising the protocol to ver. 1.80e after completion of
721 Phase III.

722 • Added the term “Universal pH test paper (ADVANTEC, 07011030)” to section 3.

723 • Added a description of the applicability domain, which was determined per the results for 93
724 test chemicals.

725 • Changed the description of the procedure for preparing test chemical solution as follows.

726 Old: If the test chemical has not been dissolved, try to dissolve it by selecting an appropriate
727 technique(s) from the following; mechanical mixture for a maximum 1-minute period using
728 a vortex mixer, sonication for a maximum 20-minute period, or heating to maximum 70°C.

729 New: If the test chemical does not dissolve readily, try using the following techniques in the
730 following order to dissolve it: a) mix mechanically for a maximum of one minute using a
731 vortex mixer, b) sonication for a maximum of 20 minutes, or c) heating to a maximum
732 temperature of 70°C. After trying each technique, adjust the temperature of each test chemical
733 solution to 28±2°C and check solubility. Move to the next step of the procedure once the test
734 chemical solution is well dissolved or homogeneously dispersed.

735 • Added a precaution that techniques for dissolving test chemicals are to be set according to

736 the physiochemical properties of the test chemicals.

737

738 The Vitrigel-EIT method was developed primarily to identify ocular non-irritants in a bottom-up
739 approach. As shown in Tables 22, the Vitrigel-EIT method demonstrated an accuracy of between 64
740 and 69% (23 to 25/36), a sensitivity of between 75 and 83% (18 to 20/24), and a specificity of 42%
741 (5/12). These figures are lower than those of in house data obtained by the lead lab and there are too
742 many false negatives for this test method to be useful in a bottom-up approach. Substances that yielded
743 either false negative or false positive results are listed in Table 23.

744

745 Table 19-1. Results for Phase III control chemicals

Set	Test chemical	FDSC					BRC					Daicel				
		Temp. (°C)*	Time lag	Intensity	Plateau level	Result	Temp. (°C)*	Time lag	Intensity	Plateau level	Result	Temp. (°C)*	Time lag	Intensity	Plateau level	Result
1	Negative control	28.0	190 (NI)	-0.03 (NI)	0 (NI)	NI	26.4	190 (NI)	0.00 (NI)	0 (NI)	NI	28.4	190 (NI)	-0.02 (NI)	0 (NI)	NI
	Positive control	28.2	0 (I)	0.45 (I)	82 (I)	I	27.5	0 (I)	0.41 (I)	75 (I)	I	28.4	0 (I)	0.52 (I)	67 (I)	I
	Reference control	27.4	0 (I)	0.20 (I)	28 (I)	I	27.5	0 (I)	0.19 (I)	34 (I)	I	28.4	0 (I)	0.24 (I)	29 (I)	I
2	Negative control	27.2	190 (NI)	-0.03 (NI)	0 (NI)	NI	27.1	190 (NI)	-0.04 (NI)	0 (NI)	NI	27.9	190 (NI)	-0.03 (NI)	0 (NI)	NI
	Positive control	27.3	0 (I)	0.44 (I)	79 (I)	I	27.2	0 (I)	0.40 (I)	73 (I)	I	27.9	0 (I)	0.40 (I)	72 (I)	I
	Reference control	27.2	0 (I)	0.19 (I)	29 (I)	I	27.3	0 (I)	0.19 (I)	35 (I)	I	27.9	0 (I)	0.14 (I)	26 (I)	I
3	Negative control	27.6	190 (NI)	-0.05 (NI)	0 (NI)	NI	27.6	190 (NI)	-0.04 (NI)	0 (NI)	NI					
	Positive control	27.5	0 (I)	0.36 (I)	65 (I)	I	27.7	0 (I)	0.50 (I)	90 (I)	I					
	Reference control	27.2	0 (I)	0.17 (I)	31 (I)	I	27.7	0 (I)	0.27 (I)	48 (I)	I					

746 * Temperature of the model at the time of exposure to the test chemical solution

747

748 Table 19-2. Results for Phase III test chemicals

No.	Test chemical	FDSC					BRC					Daicel				
		Temp. (°C)*	Time lag	Intensity	Plateau level	Result	Temp. (°C)*	Time lag	Intensity	Plateau level	Result	Temp. (°C)*	Time lag	Intensity	Plateau level	Result
3-1	2,5-Dimethyl-2,5-hexanediol	27.1	10 (I)	0.14 (I)	26 (I)	I	27.6	10 (I)	0.14 (I)	26 (I)	I	27.7	40 (I)	0.18 (I)	27 (I)	I
3-2	2-Benzyl-4-chlorophenol	28.5	0 (I)	0.40 (I)	72 (I)	I	28.0	0 (I)	0.40 (I)	72 (I)	I	27.7	0 (I)	0.40 (I)	73 (I)	I
3-3	2,2-Dimethyl butanoic acid	27.6	0 (I)	0.50 (I)	60 (I)	I	27.5	0 (I)	0.50 (I)	60 (I)	I	27.7	50 (I)	0.23 (I)	31 (I)	I
3-4	Captan	27.0	190 (NI)	-0.05 (NI)	0 (NI)	NI	27.5	190 (NI)	-0.05 (NI)	0 (NI)	NI	27.9	190 (NI)	-0.01 (NI)	0 (NI)	NI

3-5	Tetra-n-octylammonium bromide	27.5	60 (I)	0.17 (I)	23 (I)	I	27.5	60 (I)	0.12 (I)	17 (I)	I	27.6	190 (NI)	0.01 (NI)	0 (NI)	NI
3-6	Butanol	27.6	0 (I)	0.27 (I)	49 (I)	I	27.6	0 (I)	0.27 (I)	49 (I)	I	27.6	0 (I)	0.33 (I)	59 (I)	I
3-7	3- (2-Aminoethylamino)propyl] trimethoxysilane	28.1	0 (I)	0.33 (I)	60 (I)	I	27.6	0 (I)	0.33 (I)	60 (I)	I	27.6	0 (I)	0.41 (I)	73 (I)	I
3-8	Sodium dodecyl sulfate	28.4	0 (I)	0.45 (I)	81 (I)	I	27.6	0 (I)	0.45 (I)	81 (I)	I	27.6	0 (I)	0.46 (I)	82 (I)	I
3-9	m-Phenylenediamine	27.0	0 (I)	0.39 (I)	70 (I)	I	27.6	0 (I)	0.39 (I)	70 (I)	I	26.9	10 (I)	0.42 (I)	74 (I)	I
3-10	Tetraethylene glycol	27.8	0 (I)	0.24 (I)	43 (I)	I	27.7	0 (I)	0.24 (I)	43 (I)	I	26.9	20 (I)	0.20 (I)	35 (I)	I
3-30	Imidazole	28.1	90 (I)	0.24 (I)	23 (I)	I	27.8	90 (I)	0.24 (I)	23 (I)	I	27.7	80 (I)	0.31 (I)	33 (I)	I
3-32	Sodium salicylate	27.7	0 (I)	0.54 (I)	43 (I)	I	27.5	0 (I)	0.54 (I)	43 (I)	I	28.0	0 (I)	0.35 (I)	38 (I)	I
3-11	gamma-Butyrolactone	27.5	0 (I)	0.22 (I)	40 (I)	I	27.7	10 (I)	0.23 (I)	42 (I)	I	26.9	0 (I)	0.21 (I)	37 (I)	I
3-12	Methyl acetate	28.4	0 (I)	0.20 (I)	36 (I)	I	27.6	0 (I)	0.18 (I)	32 (I)	I	26.9	0 (I)	0.18 (I)	32 (I)	I
3-13	Myristyl alcohol	27.1	190 (NI)	-0.02 (NI)	0 (NI)	NI	27.3	190 (NI)	-0.05 (NI)	0 (NI)	NI	28.2	190 (NI)	-0.03 (NI)	0 (NI)	NI
3-14	2,6-Dichlorobenzoyl chloride	28.0	190 (NI)	0.00 (NI)	21 (NI)	NI	27.3	110 (I)	0.46 (I)	33 (I)	I	28.2	190 (NI)	-0.07 (NI)	0 (NI)	NI
3-15	Dibenzyl phosphate	28.1	0 (I)	0.51 (I)	71 (I)	I	27.3	0 (I)	0.39 (I)	59 (I)	I	28.2	0 (I)	0.32 (I)	57 (I)	I
3-17	1- (2-Propoxy-1-methylethoxy)-2-propanol	27.8	0 (I)	1.65 (I)	37 (I)	I	27.4	0 (I)	151 (I)	30 (I)	I	28.1	0 (I)	1.57 (I)	31 (I)	I
3-18	Camphene	27.7	160 (I)	0.08 (I)	4 (NI)	I	27.3	190 (NI)	-0.03 (NI)	0 (NI)	NI	28.4	190 (NI)	-0.01 (NI)	0 (NI)	NI
3-19	Ethyl-2-methylacetoacetate	27.2	0 (I)	0.25 (I)	46 (I)	I	27.5	10 (I)	0.19 (I)	34 (I)	I	28.3	0 (I)	0.23 (I)	42 (I)	I
3-20	Propylene glycol propyl ether	28.1	0 (I)	0.23 (I)	42 (I)	I	27.5	0 (I)	0.23 (I)	42 (I)	I	28.3	10 (I)	0.20 (I)	36 (I)	I
3-31	2-Methyl-1-pentanol	27.9	0 (I)	0.42 (I)	75 (I)	I	27.5	0 (I)	0.42 (I)	75 (I)	I	28.0	0 (I)	0.26 (I)	48 (I)	I
3-33	α -Hexylcinnamaldehyde	27.4	190 (NI)	-0.04 (NI)	0 (NI)	NI	28.0	190 (NI)	-0.04 (NI)	0 (NI)	NI	27.7	190 (NI)	-0.03 (NI)	0 (NI)	NI
3-37	Cyclopentanol	27.4	0 (I)	0.28 (I)	51 (I)	I	28.0	0 (I)	0.28 (I)	51 (I)	I	28.0	0 (I)	0.30 (I)	55 (I)	I
3-21	Methyl amyl ketone	27.4	10 (I)	0.10 (I)	20 (I)	I	27.2	10 (I)	0.10 (I)	20 (I)	I	28.3	30 (I)	0.16 (I)	26 (I)	I

3-22	2- (n-Dodecylthio)ethanol	28.7	190 (NI)	-0.05 (NI)	0 (NI)	NI	27.4	190 (NI)	-0.05 (NI)	0 (NI)	NI	28.3	190 (NI)	0.00 (NI)	0 (NI)	NI
3-23	iso-Octylthioglycolate	27.3	190 (NI)	0.00 (NI)	2 (NI)	NI	27.4	190 (NI)	0.00 (NI)	2 (NI)	NI	27.4	190 (NI)	-0.02 (NI)	0 (NI)	NI
3-24	2,4-Difluoronitrobenzene	27.8	30 (I)	0.13 (I)	20 (I)	I	27.4	30 (I)	0.13 (I)	20 (I)	I	27.4	40 (I)	0.11 (I)	18 (I)	I
3-25	tetra-Aminopyrimidine sulfate	28.7	190 (NI)	-0.09 (NI)	0 (NI)	NI	27.2	190 (NI)	-0.09 (NI)	0 (NI)	NI	27.4	190 (NI)	-0.09 (NI)	0 (NI)	NI
3-26	2,4-Pentanediol	27.4	120 (I)	0.08 (I)	7 (I)	I	27.6	120 (I)	0.08 (I)	7 (I)	I	27.4	130 (I)	0.12 (I)	8 (I)	I
3-27	iso-Octyl acrylate	27.9	190 (NI)	0.00 (NI)	0 (NI)	NI	27.7	190 (NI)	0.00 (NI)	0 (NI)	NI	27.7	190 (NI)	-0.01 (NI)	0 (NI)	NI
3-28	Silicon dioxide n-hydrate	27.3	190 (NI)	-0.04 (NI)	0 (NI)	NI	27.8	190 (NI)	-0.04 (NI)	0 (NI)	NI	27.7	190 (NI)	-0.04 (NI)	0 (NI)	NI
3-29	Potassium tetrafluoroborate	27.8	0 (I)	0.45 (I)	13 (I)	I	27.7	0 (I)	0.45 (I)	13 (I)	I	27.7	0 (I)	0.47 (I)	14 (I)	I
3-34	n,n-Dimethylguanidine sulfate	27.8	0 (I)	0.40 (I)	32 (I)	I	27.7	0 (I)	0.40 (I)	32 (I)	I	28.0	0 (I)	0.84 (I)	25 (I)	I
3-35	Toluene	28.0	80 (I)	0.16 (I)	19 (I)	I	27.7	80 (I)	0.16 (I)	19 (I)	I	28.0	30 (I)	0.12 (I)	20 (I)	I
3-36	Gluconolactone	27.2	0 (I)	0.26 (I)	10 (I)	I	27.5	0 (I)	0.26 (I)	10 (I)	I	28.0	0 (I)	0.31 (I)	9 (I)	I

749

* Temperature of the model at the time of exposure to the test chemical solution

750

751 Table 20. Results for Phase III control chemicals

Chemical	FDSC			BRC			Daicel		
	1	2	3	1	2	3	1	2	3
Negative control	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	-
Positive control	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	-
Reference	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	-

752

753 Table 21. Results for Phase III test chemicals

GHS	No.	Test chemical	FDSC	BRC	Daicel	Lead Lab
Cat. 1	3-1	2,5-Dimethyl-2,5-hexanediol	I	I	I	I
	3-2	2-Benzyl-4-chlorophenol	I	I	I	I
	3-3	2,2-Dimethyl butanoic acid	I	I	I	I
	3-4	Captan	NI	NI	NI	NI
	3-5	Tetra-n-octylammonium bromide	I	I	NI	I
	3-6	Butanol	I	I	I	I
	3-7	3-(2-Aminoethylamino)propyl] trimethoxysilane	I	I	I	I
	3-8	Sodium dodecyl sulfate	I	I	I	I
	3-9	m-Phenylenediamine	I	I	I	I
	3-10	Tetraethylene glycol	I	I	I	I
	3-30	Imidazole	I	I	I	I
	3-32	Sodium salicylate	I	I	I	I
Cat. 2A & 2B	3-11	gamma-Butyrolactone	I	I	I	I
	3-12	Methyl acetate	I	I	I	I
	3-13	Myristyl alcohol	NI	NI	NI	NI
	3-14	2,6-Dichlorobenzoyl chloride	NI	I	NI	I
	3-15	Dibenzyl phosphate	I	I	I	I
	3-17	1-(2-Propoxy-1-methylethoxy)-2-propanol	I	I	I	I
	3-18	Camphene	I	NI	NI	I
	3-19	Ethyl-2-methylacetoacetate	I	I	I	I
	3-20	Propylene glycol propyl ether	I	I	I	I
	3-31	2-Methyl-1-pentanol	I	I	I	I
	3-33	α -Hexylcinnamaldehyde	NI	NI	NI	I
3-37	Cyclopentanol	I	I	I	I	

No Category	3-21	Methyl amyl ketone	I	I	I	I
	3-22	2-(n-Dodecylthio)ethanol	NI	NI	NI	NI
	3-23	iso-Octylthioglycolate	NI	NI	NI	NI
	3-24	2,4-Difluoronitrobenzene	I	I	I	I
	3-25	tetra-Aminopyrimidine sulfate	NI	NI	NI	NI
	3-26	2,4-Pentanediol	I	I	I	I
	3-27	iso-Octyl acrylate	NI	NI	NI	NI
	3-28	Silicon dioxide n-hydrate	NI	NI	NI	NI
	3-29	Potassium tetrafluoroborate	I	I	I	I
	3-34	n,n-Dimethylguanidine sulfate	I	I	I	I
	3-35	Toluene	I	I	I	I
	3-36	Gluconolactone	I	I	I	NI

754 *In-house data from the lead lab was obtained from non-coded chemicals.

755

756 Table 22-1. Phase III contingency table used at FDSC and BRC in a bottom-up approach

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1, 2A, 2B	20	4	24
	No Category	7	5	12
Total		27	9	36

Sensitivity: 83% (20/24)

Specificity: 42% (5/12)

Accuracy: 69% (25/36)

757

758 Table 22-2. Phase III contingency table used at Daicel in a bottom-up approach

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1, 2A, 2B	18	6	24
	No Category	7	5	12
Total		25	11	36

Sensitivity: 75% (18/24)

Specificity: 42% (5/12)

Accuracy: 64% (23/36)

759

760 Table 22-3. Phase III contingency tables used at the lead lab in bottom-up approach

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1, 2A, 2B	22	2	24
	No Category	6	6	12
Total		28	8	36

Sensitivity: 92% (22/24)

Specificity: 50% (6/12)

Accuracy: 78% (28/36)

761

762 Table 23. Limitations on applicability at a bottom-up approach in phase III

No.	Test chemicals	Rank	Applicability limitation
3-4	Captan	False negatives	Insoluble after 5 m.
3-5	Tetra-n-octylammonium bromide		Insoluble after 5 m.
3-13	Myristyl alcohol		Insoluble after 5 m.
3-14	2,6-Dichlorobenzoyl chloride		pH of 2.5% solution < 5.0
3-18	Camphene		Protocol revised
3-33	α -Hexylcinnamaldehyde		
3-21	Methyl amyl ketone	False positive	
3-24	2,4-Difluoronitrobenzene		
3-26	2,4-Pentanediol		
3-29	Potassium tetrafluoroborate		
3-34	n,n-Dimethylguanidine sulfate		
3-35	Toluene		
3-36	Gluconolactone		pH of 2.5% solution < 5.0 after 10 m.

763

764 **4.2 Quality assurance**

765 All the records (data sheets and record sheets) from the participating laboratories were checked by
 766 JaCVAM, As a result, six record sheets were uncompleted. They were the record sheets on the
 767 maintenance of measuring instruments, the culture of HCE models, and the preparation and
 768 application of test chemicals at phase I and the preparation and application of test chemicals at phase
 769 II in BRC, and application of test chemicals at phase I and phase III in Daicel. Although there are
 770 these defectiveness records, JaCVAM considered these records had less effects on quality of data in the
 771 validation study.

772 **5 Discussion**

773 **5.1 Purpose of the Validation**

774 The validation study was conducted to assess the reliability (within- and between-laboratory
775 reproducibility) and relevance (predictive capacity) of the Vitrigel-EIT method with a challenging set
776 of test chemicals for which high quality in vitro and in vivo data are available. Preference should be
777 given the selection of test chemicals that were classified under UN GHS using individual animal.
778 Unfortunately, the VMT is unable to establish a correlation between results obtained using the
779 Vitrigel-EIT method and EPA categories due to a lack of individual animal data. Therefore, results
780 obtained using the Vitrigel-EIT method are correlated with UN GHS categories only. The Vitrigel-
781 EIT method was developed primarily to identify ocular non-irritants in a bottom-up approach. The
782 VMT also undertook an analysis of a top-down approach to identifying UN GHS Category 1 ocular
783 irritants for comparison with the results from a bottom-up approach.


784

785 **5.2 Transferability**

786 All test chemicals were successfully identified during Phase 0 in conformance with the results from
787 the lead laboratory, and the protocol was then revised from ver. 1.30e to ver. 1.51e. Further revisions
788 were made to eliminate inconsistencies that were identified during Phase I and Phase II testing. The
789 VMT confirmed that these inconsistencies had been resolved, thereby validating transferability of the
790 test method. A history of revisions made to the Vitrigel-EIT protocol during this process is shown in
791 Fig.7. Significant milestones during this process include:

- 792 · Changed the positive control from ethanol to benzalkonium chloride
- 793 · Adopted ethanol as reference control for checking the quality of the HCE models
- 794 · Defined a procedure for dissolving test chemicals in the culture medium (Fig.3)
- 795 · Defined a standard ambient temperature for the experiment
- 796 · Revised other minor points in the protocol

797 In order to check of transferability for regulatory use, a representative set of proficiency chemicals
798 address for regulatory acceptance in appendix 8.9.



800

801 Fig. 7 Vitrigel-EIT protocol revision history

802 **5.3 Within- and between-laboratory reproducibility**

803 The results of Phase I showed that within-laboratory reproducibility was 80% at FDSC, 90% at Daicel,
 804 and 100% at BRC, which was sufficient to satisfy the success criteria of 80% as stated in the study
 805 plan. The results of Phase II, however, were problematic and not accepted by the VMT, because
 806 irrespective of the fact that the results satisfied success criteria for between-laboratory reproducibility,
 807 all three participating laboratories obtained a false-negative result for imidazole, a GHS Category 1
 808 irritant. The results of Phase III showed that imidazole was identified correctly by all laboratories and
 809 that overall between-laboratory reproducibility was 90%, which was sufficient to satisfy the success
 810 criteria of 80% as stated in the study plan. Thus, the VMT concluded that through the process of
 811 revising the test protocol, the Vitrigel-EIT method attained an elevated level of between-laboratory
 812 reproducibility.

813 On the other hand, there were nine test chemicals that were used in both Phases II and III. Although
 814 there was a significant difference between Phases II and III in the temperature at which measurements
 815 were made, results of 7 of these 9 test substances were concordant. Only imidazole and toluene were
 816 not concordant between Phases II and III. In order to predict imidazole correctly as an irritant, the

817 temperature at which measurements were made was revised in the protocol prior to Phase III.
818 Regarding the inconsistencies for toluene in Phase II, Daicel and BRC performed the test at 22 to
819 25°C and predicted it to be a non-irritant, although FDSC performed the test at a relatively high 24 to
820 26°C and predicted it to be an irritant (Table 18). However, in Phase III, all three laboratories tested
821 at $28\pm 2^\circ\text{C}$ and predicted toluene to be an irritant. These results suggest that the temperature at which
822 measurements are made is important for achieving reproducible results. Therefore, this data also
823 indicates a high between-laboratory reproducibility for this test method.

824

825 **5.4 Predictive capacity and relevance**

826 The results obtained from thirty-six test chemicals during Phase III were analyzed to assess their
827 correlation with both existing in vitro and in vivo data and thereby evaluate predictive capacity. The
828 Vitrigel-EIT method was developed primarily to identify ocular non-irritants in a bottom-up approach.
829 Therefore, the test chemicals included UN GHS category 1, 2, 2A and 2B ocular irritants for which in
830 vivo data was available. The Vitrigel-EIT method demonstrated an accuracy of between 64 and 69%
831 (23 to 25/36), a sensitivity of between 75 and 83% (18 to 20/24), and a specificity of 42% (5/12).
832 Sensitivity was low due to six false negatives and specificity (predictive capacity for identifying non-
833 irritants) was low due to seven false positives, as shown in Table 23. The VMT requested the further
834 analysis to determine whether or not predictive capacity could be improved by defining the
835 applicability domain. Ultimately, it was determined that although the results of the validation
836 confirmed an elevated level of reproducibility for this assay, the sample size was insufficient either to
837 evaluate predictive capacity or define a proper applicability domain. Therefore, the VMT
838 recommended that data obtained at the lead laboratory should be used to define an applicability
839 domain suitable for use in a regulatory context.

840 Total 132 test chemicals were tested at the lead laboratory and were composed of 118 test chemicals
841 (Appendix 8.10 and Appendix 8.11) including 22 used during Phase III and additional 14 chemicals
842 during Phase III. According to the latest version of the protocol, however, the available data limited
843 at lead laboratory were 57 chemicals tested at $28\pm 2^\circ\text{C}$ in 96 chemicals subtracted 36 chemicals for

844 Phase III from the total 132 chemicals. Hence, the predictive capacity was evaluated by the 93
845 results comprise the data for 36 chemicals during Phase III shown in Table 21 and for 57 chemicals
846 obtained at the lead laboratory shown in Appendix 8.8. The test chemicals were selected to ensure that
847 a diverse range of substances were represented, and aspects such as eye-irritant level per UN GHS
848 categories, physical state, chemical class. The 93 test chemicals are composed of 56 liquids and 37
849 solids. Also, their contents are 28 Category 1 chemicals, 32 Category 2, 2A, 2B chemicals, and 33 No
850 Category chemicals by UN GHS classification. There were 36 coded chemicals tested for Phase III
851 and 57 non-coded chemicals were tested at the lead laboratory. These 93 test chemicals were examined
852 by the Vitrigel-EIT method in accordance with the protocol versions described in Chapter 3.1.3.4 and
853 Appendix 8.8. However, the temperature at which all measurements were made during the chemical
854 exposure experiments was strictly controlled at $28\pm 2^{\circ}\text{C}$ (Table 19 and Appendix 8.8). Thus we
855 consider this data sufficient for assessing the suitability of the Vitrigel-EIT method for use in a bottom-
856 up approach for identifying ocular non-irritants and in a top-down approach for identifying UN GHS
857 Category 1 ocular irritants. In a bottom-up approach, 60 of the test chemicals were classified as irritant
858 and the other 33 as non-irritant, with results for 73 of the 93 test chemicals matching their UN GHS
859 categories. In contrast, 10 of the 60 test chemicals classified as irritants by in vivo data were identified
860 as non-irritants, a false-negative rate of 17%. Additionally, 10 of the 33 test chemicals classified as
861 non-irritants under UN GHS were identified as irritants, a false-positive rate of 30%. Thus, the
862 Vitrigel-EIT method achieved a sensitivity of 83%, a specificity of 70%, and an accuracy of 78%, as
863 shown in Table 24-1. Data from the lead laboratory also demonstrated that predictive capacity could
864 be improved by expanding the sample size. For example, the specificity achieved in Phase III of this
865 validation study was lower than that obtained from the data of 33 non-irritants resulted in a higher
866 specificity. The list of test chemicals that were either false negative or false positives is shown in Table
867 25.

868 On the other hand, analysis per a top-down approach for identifying UN GHS Category 1 ocular
869 irritants was also performed as a part of this validation study, as shown in Tables 24-2. Regarding
870 identifying test chemicals classified as UN GHS Category 1 in a top-down approach, the Vitrigel-EIT

871 method demonstrated a sensitivity of 89% (25/28), a specificity of 46% (30/65), and an accuracy of
 872 59% (55/93). Specificity is an important criterion in a top-down approach, which means that Vitrigel-
 873 EIT method is not well suited for use in a top-down approach to identifying UN GHS Category 1
 874 ocular irritants.

875 Table 24-1. Contingency table used for 93 test chemicals in a bottom-up approach

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1, 2A, 2B	50	10	60
	No Category	10	23	33
Total		60	33	93

Sensitivity: 83% (50/60)

Specificity: 70% (23/33)

Accuracy: 78% (73/93)

876 Table 24-2. Contingency table used for 93 test chemicals in a top-down approach

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1	25	3	28
	Cat.2A, 2B, No Category	35	30	65
Total		60	33	93

Sensitivity: 89% (25/28)

Specificity: 46% (30/65)

Accuracy: 59% (55/93)

877
 878
 879
 880
 881
 882
 883
 884
 885
 886
 887
 888

889 Table 25. False test chemicals in a bottom-up approach for 93 test chemicals

No.*	Test chemicals	Rank	Applicability limitation
3-4	Captan	False negatives	Insoluble after 5 min.
3-13	Myristyl alcohol		Insoluble after 5 min.
3-14	2,6-Dichlorobenzoyl chloride		pH of 2.5% solution \leq 5.0
3-18	Camphene		Protocol revised
3-33	α -Hexylcinnamaldehyde		
19	2-Methylbutanoic acid		pH of 2.5% solution \leq 5.0
24	3,3'-Dithiodipropionic acid		pH of 2.5% solution \leq 5.0
26	Ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridinepropanoate		pH of 2.5% solution \leq 5.0
39	6-Methylpurine		
40	Lactic acid		pH of 2.5% solution \leq 5.0
3-21	Methyl amyl ketone	False positive	
3-24	2,4-Difuronitrobenzene		
3-26	2,4-Pentanediol		
3-29	Potassium tetrafluoroborate		
3-34	n,n-Dimethylguanidine sulfate		
3-35	Toluene		
3-36	Gluconolactone		pH of 2.5% solution $<$ 5.0 after 10 min.
8	Methyl isobutyl ketone		
28	Triethanolamine		
37	Cyclohexanone		

890 *Each number corresponds to the number in Table 21 and Appendix 8.8.

891 **5.7 Applicability domain**

892 Analysis of the false-negative reactions shows that five of the ten false-negative chemicals were acidic,
893 and the 2.5% solutions used for exposure had a pH level lower than 5, as shown in Table 25. The
894 TEER values of the HCE models after exposures to each of these five acidic test chemicals that yielded
895 false-negatives increased from their initial values. Interestingly, it was reported that isolated rabbit
896 esophageal mucosal epithelium and normal human bronchial epithelial cell layers in culture displayed
897 increased TEER values when exposed to weak acidic solutions (Farré et al., 2008; Oshima et al., 2012).
898 On the other hand, two of the five non-acidic false-negative chemicals were water-insoluble solids
899 that were easily separated from the culture medium at room temperature, as shown in Table 25.
900 Therefore, the lead laboratory added two restrictions to the applicability domain in consideration of
901 above scientific rationales:

- 902 • Exclude all test chemicals that have a pH level of 5 or less in solution (affected 11 tested
903 chemicals).
- 904 • Exclude all solids that have both a logP value of 2.5 or more and a density of either less than
905 0.95 g/cm³ or over 1.10 g/cm³ (affected 6 test chemicals).

906 Under this applicability domain, 17 of the original 93 test chemicals were excluded, as shown in
907 Tables 26, which improve sensitivity from 83 to 93%, specificity from 70 to 69%, and accuracy from
908 78 to 83%, as shown in Table 27.

909 Of the 44 irritants, one other that yielded a false-negative was 6-methylpurine, a non-acidic, water-
910 soluble powder. The reason for the false-negative judgment is currently under investigation. The
911 classification of the test chemical in vivo was identified as “Study Criteria Not Met” because the study
912 was terminated before 21 days without full reversibility (scores equal to 0) of all endpoints in all
913 animals, in the absence of any other effects driving a Cat 1 classification (Barroso et al, 2017).

914 Eight of the 36 test chemicals in Phase III are excluded under the new applicability domain:

- 915 No. 3-2 2-Benzyl-4-chlorophenol (insoluble)
- 916 No. 3-3 2,2-Dimethyl butanoic acid (pH ≤ 5)
- 917 No. 3-4 Captan (insoluble)

918 No. 3-5 tetra-n-Octylammonium bromide (insoluble)

919 No. 3-13 Myristyl alcohol (insoluble)

920 No. 3-14 2,6-Dichlorobenzoyl chloride (pH ≤ 5)

921 No. 3-15 Dibenzyl phosphate (pH ≤ 5)

922 No. 3-25 tetra-aminopyrimidine sulfate (pH ≤ 5)

923 After excluding these eight test chemicals, sensitivity improved from between 75 and 83% to between
924 88 and 94% (15 to 16/17), specificity changed from 42% to 36% (4/11), and accuracy improved from
925 between 64 and 69% to between 68 and 71% (19 to 20/28).

926 Of the 17 irritants, two others that yielded false-negatives were No. 3-18, camphene, and No. 3-33,
927 alpha-hexylcinnamaldehyde. Camphene is a waxy, water-insoluble solid, and the false-negative was
928 due to the technique used for dissolving, as described in section 4.1.4 Phase III. Alpha-
929 hexylcinnamaldehyde is a water-immiscible liquid and was identified as an irritant by the lead
930 laboratory (Yamaguchi, 2016). The reason for the discordance of the judgment is currently under
931 investigation, although the classification of alpha-hexylcinnamaldehyde in several studies in vivo was
932 reported as NC and 2A or higher (Barroso et al, 2017). In consideration of the Draize eye test
933 Reference Database (DRD; Barroso et al, 2017), additional testing was performed in the lead
934 laboratory using 114 test chemicals selected from the list of DRD (Appendix 8.13, 8.14).

935

936 Table 26-1. Limitations on applicability (pH level 5 or less in 2.5% solution) in a bottom-up approach

No.*	Test chemical	GHS category	Vitrigel-EIT results	pH
3-3	2,2-Dimethyl butanoic acid	1		4
3-14	2,6-Dichlorobenzoyl chloride	2A	False negative	3
3-15	Dibenzyl phosphate	2A		3
3-25	tetra-Aminopyrimidine sulfate	NC		3
19	2-Methylbutanoic acid	1	False negative	4
24	3,3'-Dithiodipropionic acid	2B	False negative	4
26	Ethyl 2,6-dichoro-5-fluoro-beta-oxo-3-pyridinepropanoate	2B	False negative	5

27	3-Chloropropionitrile	2B		5
40	Lactic acid	1	False negative	3
49	Citric acid	2A		3
52	Glycolic acid	2		4

937 *Each number corresponds to the number in Table 21 and Appendix 8.8.

938

939 Table 26-2. Limitations on applicability (solid chemicals with a logP value of 2.5 or more and a density
940 under 0.95 g/cm³ or over 1.10 g/cm³ in a bottom-up approach.

No.*	Test chemical	GHS category	Vitrigel-EIT results	LogP	Density (g/cm ³)
3-2	2-Benzyl-4-chlorophenol	1		3.60	1.19
3-4	Captan	1	False negative	2.80	1.74
3-5	Tetra-n-octylammonium bromide	1		3.45	0.94
3-13	Myristyl alcohol	2A	False negative	6.03	0.82
22	Acid red 92	2		7.13	2.16
35	Potassium laurate	1		4.57	1.12

941 *Each number corresponds to the number in Table 21 and Appendix 8.8

942 Table 27. Contingency tables used for 76 test chemicals within the applicability domain in bottom-up
943 approach.

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1, 2A, 2B	41	3	44
	Not Classified	10	22	32
Total		51	25	76

Sensitivity: 93% (41/44)

Specificity: 69% (22/32)

Accuracy: 83% (63/76)

944

945 5.6 Other analysis

946 The VMT discussed the use of an area over the curve (or weighted area under the curve: wAUC) of
947 the TEER measurement to obtain high predictive capacity and requested that the biostatisticians
948 develop new prediction algorithm. As a result, a new statistical algorithm was designed and proposed
949 to improve the predictive capacity, particularly in the area of specificity.

950 The proposed algorithm involved evaluating the eye irritancy of a test chemical using two parameters:
951 (1) the TEER value measured at the final time point (180 seconds) and (2) the decrease in TEER value
952 across the 180-second measurement period. A suitable cut-off value was determined for these two
953 parameters based on the results of Phase III and in reference to the Youden index. The sensitivity,
954 specificity, and accuracy obtained with the proposed algorithm were then compared with those
955 obtained with the original algorithm. Finally, the validity of the proposed algorithm was confirmed
956 using the results obtained from 118 test chemicals by the lead laboratory (Yamaguchi et al., 2016).
957 Using a cut-off value of 0.15 for the decrease in TEER value across the measurement period yielded
958 a sensitivity of 67%, a specificity of 92%, and an accuracy of 75%. Based on these results, the VMT
959 decided not to accept the new prediction algorithm to analyze data from this validation study.

960

961 **5.7 Comparison with other alternative to ocular irritation assay**

962 The Vitrigel-EIT method was developed by measuring relative changes in TEER for a period of 180
963 second after exposure to 30 test chemicals as previously reported (Yamaguchi et al., 2013). It is
964 generally accepted that at least 100 substances should be tested to assess the predictive capacity of a
965 new test method, and to this end, the developers tested a total of 118 test chemicals of various physical
966 and chemical properties (Yamaguchi et al., 2016). The results of this testing showed that the Vitrigel-
967 EIT test method had a predictive capacity that was comparable to other test methods for which OECD
968 test guidelines are currently being developed. For example, the EpiOcular-EIT method demonstrated
969 a sensitivity of 98%, a specificity of 73%, and an accuracy of 85% (Kaluzhny et al., 2011). Used in a
970 bottom-up approach, the short time exposure (STE) test demonstrated a sensitivity of 88%, a
971 specificity of 80%, and an accuracy of 85% (ICCVAM, 2013) and the predictive capacity of the
972 Vitrigel-EIT method is similar with ones of the other methods (the sensitivity of 93%, a specificity of
973 69%, and an accuracy of 83%) under the applicability domain.

974 In addition, the vitrigel-EIT method has some advantages in required time, practicality and cost shown
975 in Table 28. Each of these test methods, however, yields some false-negatives or false-positives. Thus,
976 it is important to clarify the mechanism that results in these false-negatives and false-positives,

977 particularly when developing an in vitro test method suitable for use as an alternative to in vivo testing.
 978 The VMT has confirmed the applicability domain proposed by the lead laboratory. Meanwhile,
 979 scientists at the lead laboratory consider immuno-histology to be a powerful tool for clarifying the
 980 mechanism of false-positive reactions, because the culture model can be easily utilized as frozen
 981 sections after completing the Vitrigel-EIT.

982

983 Table 28. Comparative table between the Vitrigel-EIT method and other test methods.

Test method	Vitrigel-EIT	STE (TG491)	EpiOcular-EIT (TG492)
Required time (for 24 test)	6days for preparing HCE models 2hours for chemicals exposure experiment	4days for preparing SIRC cell monolayer 3hours for chemical exposure experiment	1day for preparing HCE models 9hours (liquid) or 30hours (solid) for chemical exposure experiment
Practicality	Easy	Easy	Difficult to remove test chemicals from HCE models
Cost	¥84,000 for ad-MED Vitrigel	Relatively low	¥144,000 for HCE models
Mechanistic relevance	Epithelial barrier function	Cell viability	Cell viability
Limitation of test chemicals	Exclude acidic and easily separable water-insoluble solids	Exclude highly volatile substances and all solid chemicals other than Surfactants	Colored sample (need additional procedure)

984

985

986

987 **6 Conclusion**

988 This study was performed in the spirit of GLP at three participating laboratories using a total of 42
989 test chemicals to validate the Vitrigel-EIT method for within- and between-laboratory reproducibility
990 as well as for the capacity to distinguish non-irritants from irritants in a bottom up approach.

991 The results showed good within-laboratory reproducibility between 80 and 100% as well as an
992 excellent between-laboratory reproducibility of 92% (33/36). Unfortunately, predictive capacity for
993 distinguishing non-irritants from irritants per UN GHS categories in a bottom-up approach was not
994 favorable because of a high incidence of false negatives as high as 17% (10/60). After considerable
995 review of the data, the applicability domain was revised to exclude test chemicals that have a pH level
996 of 5 or less in solution as well as those that are solids and have both a logP value 2.5 or more and a
997 density of either less than 0.95 g/cm³ or a density of over 1.10 g/cm³, which improved the false
998 negative rate to 7% (3/44).

999 From the above described results, the VMT concluded that the Vitrigel-EIT method demonstrated
1000 excellent within- and between-laboratory replicability and that, with a carefully defined applicability
1001 domain, it is a useful alternative to the Draize test for distinguishing test chemicals that are ocular non-
1002 irritants from those that are irritants.

1003

1004 Acknowledgments

1005 This work was supported by Agri-Health Translational Research Project (no. 6320) from the Ministry
1006 of Agriculture, Forestry and Fisheries of Japan.

1007

1008 **7 References**

1009 Araki-Sasaki, K., Ohashi, Y., Sasabe, T., Hayashi, K., Watanabe, H., Tano, Y., and Handa, H., “An
1010 SV40-immortalized human corneal epithelial cell line and its characterization,” *Investigative*
1011 *Ophthalmology & Visual Science* 36 (1995): 614–621.

1012 Barroso, J., Pfannenbecker, U., Adriaens, E., Alépée, N., Cluzel, M., De Smedt, A., Hibatallah, J.,
1013 Klaric, M., Mewes, K.R., Millet, M., Templier, M., and McNamee, P., “Cosmetics Europe
1014 compilation of historical serious eye damage/eye irritation in vivo data analysed by drivers of

1015 classification to support the selection of chemicals for development and evaluation of
1016 alternative methods/strategies: the Draize eye test Reference Database (DRD),” *Archives of*
1017 *Toxicology* 91 (2017): 521–547.

1018 Kim, C. W., Go, R. E., Lee, G. A., Kim, C. D., Chun, Y. J., and Choi, K. C., “Immortalization of
1019 human corneal epithelial cells using simian virus 40 large T antigen and cell characterization,”
1020 *Journal of Pharmacological and Toxicological Methods* 78 (2016): 52–57.

1021 Draize, J., Woodard, G., and Calvery, H., “Methods for the study of irritation and toxicity of substances
1022 applied topically to the skin and mucous membranes,” *The Journal of Pharmacology and*
1023 *Experimental Therapeutics* 82 (1944): 377–390.

1024 European Centre for Ecotoxicology and Toxicology of Chemicals, *TR 048 Eye Irritation: Reference*
1025 *Chemicals Data Bank*, 2nd ed., Brussels: ECETC, 1998.

1026 Farré, R., van Malenstein, H., De Vos, R., Geboes, K., Depoortere, I., Vanden Berghe, P., Fornari, F.,
1027 Blondeau, K., Mertens, V., Tack, J., and Sifrim, D., “Short exposure of esophageal mucosa to
1028 bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and
1029 provoke dilated intercellular spaces,” *Gut*. 57 (2008): 1366–1374.

1030 Hartung, T., Bremer, S., Casati, S., Coecke, S., Corvi, R., Fortaner, S., Gribaldo, L., Halder, M.,
1031 Hoffmann, S., Janusch Roi, A., Prieto, P., Sabbioni, E., Scott, L., Worth, A., and Zuang, V., “A
1032 modular approach to the ECVAM principles on test validity,” *ATLA* 32 (2004): 467–472.

1033 National Institute of Environmental Health Sciences, “Appendix J: NICEATM Analysis: Reduced
1034 Eye Hazard Labeling Resulting from Using Globally Harmonized System (GHS) Instead of
1035 Current U.S. Regulatory Classification Criteria,” *ICCVAM Test Method Evaluation Report:*
1036 *Current Validation Status of In Vitro Test Methods Proposed for Identifying Eye Injury Hazard*
1037 *Potential of Chemicals and Products*, National Institutes of Health Publication No. 10-7553,
1038 National Institutes of Health (2010):
1039 http://ntp.niehs.nih.gov/iccvam/docs/ocutox_docs/invitro-2010/appj-analysis.pdf.

1040 *Short Time Exposure (STE) Test Method Summary Review Document*, National Institutes of Health
1041 (2013): http://ntp.niehs.nih.gov/iccvam/docs/ocutox_docs/STE-SRD-NICEATM-508.pdf.

1042 Kaluzhny, Y., Kandàrovà, H., Hayden, P., Kubilus, J., d'Argembeau-Thornton, L., and Klausner, M.,
1043 "Development of the EpiOcular™ Eye Irritation Test for Hazard Identification and Labelling
1044 of Eye Irritating Chemicals in Response to the Requirements of the EU Cosmetics Directive
1045 and REACH Legislation," *ATLA* 39 (2011): 339–364.

1046 Cooper-Hannan, R., Harbell, J., and Coecke, S., "The principles of good laboratory practice:
1047 application to in vitro toxicology studies," *ATLA* 27 (1999): 539–577

1048 Organisation for Economic Co-operation and Development, *Principles of Good Laboratory Practice
1049 and Compliance Monitoring*, OECD ENV/MC/CHEM (98)17 (1998):
1050 [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/mc/chem\(98\)17&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/mc/chem(98)17&doclanguage=en).
1051

1052 *OECD Series on Testing and Assessment, Number 34: Guidance Document on the Validation and
1053 International Acceptance of New or Updated Test Methods for Hazard Assessment*, OECD
1054 ENJ/JM/MONO(2005)14, OECD Publishing (2005):
1055 [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO\(2005\)14&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2005)14&doclanguage=en).
1056

1057 "Test No. 491: Short Time Exposure In Vitro Test Method for Identifying i) Chemicals Inducing
1058 Serious Eye Damage and ii) Chemicals Not Requiring Classification for Eye Irritation or
1059 Serious Eye Damage," *OECD Guidelines for the Testing of Chemicals, Section 4*, OECD
1060 Publishing (2015): <http://dx.doi.org/10.1787/9789264242432-en>.

1061 "Test No. 492: Reconstructed human Cornea-like Epithelium (RhCE) Test Method for Identifying
1062 Chemicals Not Requiring Classification and Labelling for Eye Irritation or Serious Eye
1063 Damage," *OECD Guidelines for the Testing of Chemicals, Section 4*, OECD Publishing (2015):
1064 <http://dx.doi.org/10.1787/9789264242548-en>.

1065 Scott, L., Eskes, C., Hoffmann, S., Adriaens, E., Alepée, N., Bufo, M., Clothier, R., Facchini, D., Faller,
1066 C., Guest, R., Harbell, J., Hartung, T., Kamp, H., Varlet, B. L., Meloni, M., McNamee, P.,
1067 Osborne, R., Pape, W., Pfannenbecker, U., Prinsen, M., Seaman, C., Spielmann, H., Stokes, W.,
1068 Trouba, K., Berghe, C. V., Gothem, F. V., Vassallo, M., Vinardell, P., and Zuang, V., "A

1069 proposed eye irritation testing strategy to reduce and replace in vivo studies using Bottom-Up
1070 and Top-Down approaches,” *Toxicology In Vitro* 24 (2010): 1–9.

1071 Takahashi, Y., Hayashi, K., Abo, T., Koike, M., Sakaguchi, H., and Nishiyama, N., “The Short Time
1072 Exposure (STE) test for predicting eye irritation potential: Intra-laboratory reproducibility and
1073 correspondence to globally harmonized system (GHS) and EU eye irritation classification for
1074 109 chemicals,” *Toxicology In Vitro* 25 (2011): 1425–1434.

1075 Takezawa, T., Ozaki, K., Nitani, A., Takabayashi, C., and Shimo-Oka, T., “Collagen vitrigel: a novel
1076 scaffold that can facilitate a three-dimensional culture for reconstructing organoids,” *Cell*
1077 *Transplantation* 13 (2004): 463–473.

1078 Takezawa, T., Ozaki, K., and Takabayashi, C., “Reconstruction of hard connective tissue utilizing a
1079 pressed silk sheet and type-I collagen as the scaffold for fibroblasts,” *Tissue Engineering*
1080 (2007a) 13: 1357–1366.

1081 Takezawa, T., Nitani, A., Shimo-Oka, T., and Takayama, Y., “A protein-permeable scaffold of a
1082 collagen vitrigel membrane useful for reconstructing crosstalk models between two different
1083 cell types,” *Cells, Tissues, Organs* 185 (2007b): 237–241.

1084 Takezawa, T., Takeuchi, T., Nitani, A., Takayama, Y., Kino-Oka, M., Taya, M., and Enosawa S.
1085 “Collagen vitrigel membrane useful for paracrine assays in vitro and drug delivery systems in
1086 vivo,” *Journal of Biotechnology* 131 (2007c): 76–83.

1087 Takezawa, T., McIntosh-Ambrose, W., and Elisseeff, J. H., “A novel culture model of rabbit corneal
1088 epithelium utilizing a handy scaffold of collagen vitrigel membrane and its cryopreservation,”
1089 *Alternatives to Animal Testing and Experimentation* 13 (2008): 176.

1090 Takezawa, T., Nishikawa, K., and Wang, P. C., “Development of a human corneal epithelium model
1091 utilizing a collagen vitrigel membrane and the changes of its barrier function induced by
1092 exposing eye irritant chemicals,” *Toxicology In Vitro* 25 (2011a): 1237–1241.

1093 Takezawa, T., Aoki, S., Oshikata, A., Okamoto, C., Yamaguchi, H., Narisawa, Y., and Toda, S., “A
1094 novel material of high density collagen fibrils: A collagen xerogel membrane and its application
1095 to transplantation in vivo and a culture chamber in vitro,” *24th European Conference on*

1096 *Biomaterials* (2011b): 831 (Abstract).

1097 “A novel material of high density collagen fibrils: A collagen xerogel membrane and its
1098 application to transplantation in vivo and a culture chamber in vitro,” *24th European*
1099 *Conference on Biomaterials*, Bologna: MEDIMOND, 2011c, 181–185.

1100 Uematsu, M., Kumagami, T., Kusano, M., Yamada, K., Mishima, K., Fujimura, K., Sasaki, H., and
1101 Kitaoka, T., “Acute corneal epithelial change after instillation of benzalkonium chloride
1102 evaluated using a newly developed in vivo corneal transepithelial electric resistance
1103 measurement method” *Ophthalmic Research* 39 (2007): 308–314.

1104 United Nations, *Globally Harmonized System of Classification and Labeling of Chemicals*, 5th ed.
1105 (ST/SG/AC.10/30/Rev.5), New York: United Nations, 2013.

1106 Yamaguchi, H., Kojima, H., and Takezawa, T., “Vitrigel-eye irritancy test method using HCE-T cells,”
1107 *Toxicological Sciences* 135 (2013): 347–355.

1108 “Predictive performance of the Vitrigel-eye irritancy test method using 118 chemicals,” *Journal*
1109 *of Applied Toxicology* 36 (2016): 1025–1037.

1110 Yamasaki, K., Kawasaki, S., Young, R. D., Fukuoka, H., Tanioka, H., Nakatsukasa, M., Quantock,
1111 A. J., and Kinoshita, S., “Genomic aberrations and cellular heterogeneity in SV40-
1112 immortalized human corneal epithelial cells,” *Investigative Ophthalmology & Visual Science*
1113 50 (2009): 604–613.

1114 York, M., and Steiling, W., “A critical review of the assessment of eye irritation potential using the
1115 Draize rabbit eye test,” *Journal of Applied Toxicology* 18 (1998): 233–240.